ðŽãã€ã¯ã»ã€ãŒãã³å士ãããã¥ã«ã³ãã«ã¯ç¶±é éåã§åœéåäºè£å€æã«æåºããŠãã46ããŒãžã®èšŽèšæžé¡ã玹ä»ããŸãã
ãã¹ãŠèªå翻蚳ããŠããŸãã
æ
å ±å
ã¯ãã¡ãã«ãªããŸããïŒPDFããïŒð
ãã€ã¯ã»ã€ãŒãã³å士ãããã¥ã«ã³ãã«ã¯ç¶±é éåã§åœéåäºè£å€æã«æåºããŠãã46ããŒãžã®èšŽèšæžé¡ã玹ä»ããŸãã
ãã®äžä»¶ã«ã¯ã解ãæããã¹ãããšããããããããŸãããããã§ã¯ããã€ãã®ãã€ã³ãã玹ä»ããŸãã
1) ãã¡ãŠãããã«ïŒã¡ãªã³ãã»ã²ã€ããããªã¹ã»ãžã§ã³ãœã³ã4倧ã¯ã¯ãã³è£œé äŒç€Ÿã®CEOãã被åãšããŠãªã¹ãã¢ãããããŠããã
2) ã¯ã¯ãã³ãPCRãã¹ããæ©èœç²åŸãæ©èœç²åŸç 究ãžã®ç±³åœã®è³éæäŸãæ°Žé
žåã°ã©ãã§ã³ïŒ7ããŒãžã¯å¿
èªè³æïŒãçã®æ°ã®èšåŒµããã¹ã¯ã®å¹æã®ãªãã代æ¿æ²»çããã®ä»å€ãã®å€§è¡ãæžå¿µããçç±ã蚎ç¶ã«èšèŒãããŠããŸãã
3) ã€ãã³ã201ãã¢ãžã§ã³ã21/30ã1930幎代ãã€ããšã®é¡äŒŒæ§ãªã©ãæããããŠããŸãã
æåããæåŸãŸã§èªãã°ããã®30幎éãã©ã®ããã«åœ¢æããããã®ãCovidãã€ãã³ãã«è³ã£ããããããããã§ãããã
30åã»ã©æéããšã£ãŠããã®ãã¡ã€ãªã³ã°ã«ç®ãéãããšã匷ããå§ãããŸãã
åœéåäºè£å€æ æ€å¯å®äºåæ ã³ãã¥ãã±ãŒã·ã§ã³ãº
ãã¹ããªãã£ã¹ããã¯ã¹ 19519 2500 CM The Hague
ãªã©ã³ã
EMAIL: otp.informationdesk@icc-cpi.int
åœéåäºè£å€æã«ãããŠïŒããŒãæ¡çŽèŠçŽ15.1æ¡ã53æ¡ïŒ
èŠæ
ã®å¯Ÿè±¡
- ãã¥ã«ã³ãã«ã¯ç¶±é ã«éåããè¡çº
- ããŒãèŠçšç¬¬6æ¡éå
- ããŒãèŠçšç¬¬7æ¡éå
- ããŒã8æ¡éå
- ããŒãèŠçšç¬¬8æ¡bis3éå
åºç¯ãªäž»åŒµãšåå°ã®ææžã«åºã¥ããæã
ã¯ãè±åœã«ããããã¥ã«ã³ãã«ã¯ç¶±é ã®å€æ°ã®éåã人éã«å¯Ÿãã眪ãæŠäºç¯çœªããã³äŸµç¥ã®çœªã®è²¬ä»»è
ãåçºãããããããã®åœã®å人ã«éå®ããããã®ã§ããªãã
å 害è
ãã¡
è±åœéŠçž BORIS JOHNSONãè±åœæé«å»åŠè²¬ä»»è
å
Œè±åœæ¿åºæé«å»åŠé¡§å CHRISTOPHER WHITTYãïŒåïŒåççé·å® MATTHEW HANCOCKãïŒçŸïŒåççé·å® SAJID JAVIDãå»è¬åã»å»çåèŠå¶åºïŒMHRAïŒé·å® JUNE RAINE,äžçä¿å¥æ©é¢ïŒWHOïŒäºåå±é· TEDROS ADANHOM GHEBREYESUS ãã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£å
±åäŒé· WILLIAM GATES III ãã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£å
±åäŒé· MELINDA GATES ãã¡ã€ã¶ãŒäŒé·å
ŒCEO ALBERT BOURLA ã¢ã¹ãã©ãŒãã«CEO STEPHANE BANCEL ã¢ããCEO PASCAL SORIOT ãã«ã»ã²ã€ã財å£äŒé·å
ŒCEO
ãžã§ã³ãœã³ã»ã¢ã³ãã»ãžã§ã³ãœã³ ALEX GORSKY ããã¯ãã§ã©ãŒè²¡å£äŒé· RAJIV SHAH åœç«ã¢ã¬ã«ã®ãŒã»ææçç 究æïŒNIAIDïŒæé· ANTHONY FAUCI äžççµæžãã©ãŒã©ã åµèšè
å
ŒäŒé· KLAUS SCWAB EcoHealth AllianceäŒé· PETER DASZACK
被害è
(è€æ°)ã€ã®ãªã¹åœæ°
å¿åè
ãã³ãã»ããŒãºïŒHannah RoseïŒ åŒè·å£«ã»äººæš©æŽ»å家
ãã€ã¯ã»ã€ã§ãã³å士 - æ¯ç©åŠã§çååŠã®åŠäœãååŸããåŒåžåšè¬çåŠã§ç 究ããŒã¹ã®å士å·ãååŸããæè³æ Œã®ã©ã€ããµã€ãšã³ã¹ç 究è
ãå
ãã¡ã€ã¶ãŒç€Ÿã¢ã¬ã«ã®ãŒã»åŒåžåšç 究éšéã®å¯ç€Ÿé·å
ŒããŒããµã€ãšã³ãã£ã¹ã
Piers Corbyn - 倩äœç©çåŠè
ã掻å家
ããŒã¯ã»ã»ã¯ã¹ãã³ - å
èŠå¯å®
John O'Loony - è¬åå±ã掻å家
ãžã§ããŒã»ãã¯ã¹ã〠- 掻å家
ã«ã€ãŒãºã»ã·ã§ãããã«ã - çè·åž«ã人暩掻å家
æ³å®ä»£ç人ããã³æ¬ç±å°ã®éžæ
æ¬æç¶ãã«ãããç³è«è
ã®ä»£ç人ã¯ãHannah Rose Email: hannahroses111@hotmail.com ãåããŸãã
åŸã£ãŠããã®åŸã®ãã¹ãŠã®éä¿¡ã¯ãäžèšã®é»åã¡ãŒã«ã¢ãã¬ã¹ã«ã®ã¿éä¿¡ããããã®ãšããŸãããã®æ¹æ³ã§éãããè£å€æèŠçšã®æå³ã«ããããã¹ãŠã®éç¥ã¯ãæå¹ãšã¿ãªãããŸãã
æ€äºæ®¿
1 ãã®é£çµ¡ããã³èŠæ
ã¯ã2000幎10æ4æ¥ã«åœéé£åäºåç·é·ã«å¯èšãããåœéåäºè£å€æã®ããŒãèŠçšãžã®è±åœã®å çã«åºã¥ããæ€å¯å®äºåæã«æäŸããããã®ã§ãã
2 ç§ãã¡ã¯ãå°å
ã®è±åœèŠå¯ãè±åœã®è£å€æãéããŠãã®äºä»¶ãæèµ·ããããšããŸããããæåãããäœåºŠè©Šã¿ãŠãèŠå¯ã«ãè£å€æã«ãäºä»¶ãšããŠç»é²ãããããšã¯ãããŸããã§ãããICCã¯ãåœå®¶ãææ»ã蚎远ãè¡ãããšãæãŸãããããã¯è¡ããªãå Žåã«ã®ã¿èšŽè¿œããïŒ17æ¡1é
ïŒããšå®£èšããŠããŸããä»åã®äºä»¶ã¯ãã®ãããªã±ãŒã¹ã§ãããã ããããç§ãã¡ã¯ICCã«çŽæ¥èšŽããŠããã®ã§ãã
A.èæ¯
3 ã³ãããŠã€ã«ã¹ãã¯ã¯ãã³ãã¯
ã¯ãé©æ°çãªå»çè¡çºã§ãããããã®å»çã«é¢ããèŠå¶æ³ïŒ2012幎ïŒç¬¬174æ¡ã«åºã¥ãäžæçãªèªå¯ãåããã«éããŸããããã®æ²»çæ³ã®æ£è
ã«ãããé·æçãªå¹æãå®å
šæ§ã¯æªç¥æ°ã§ããã³ãããŠã€ã«ã¹ãã¯ã¯ãã³ãã¯ãåæm-RNAæè¡ãäžçã§åããŠå°å
¥ãããã®ã§ããããããŸã§ã®ãã¹ãŠã®äºé²æ¥çš®ã¯ãäžæŽ»æ§åãŸãã¯åŒ±æ¯åãããŠã€ã«ã¹ãäœå
ã«å°å
¥ããŠãããã«å¯Ÿããå
ç«ç³»ã®èªç¶ãªèŠéãèªçºãããšãããå
šãç°ãªãæ¹æ³ã§è¡ãããŠããããšã«æ³šç®ããããšãéèŠã§ããDr Mike Yeadonã詳述ããããã®é©æ°çãªå»çã«ãã£ãŠäºæ³ããããªã¹ã¯ã¯ãæ¬èŠæ±æžã®ä»é²1ãšããŠããã«æ·»ä»ãããŠããŸãã
4 COVID-19ã¯ã¯ãã³ã®ç¬¬3çžè©Šéšã¯ãã¹ãŠé²è¡äžã§ããã2022幎æ«ãã2023幎åé ãŸã§çµäºããäºå®ã¯ãããŸããããããã£ãŠããã®ã¯ã¯ãã³ã¯çŸåšå®éšçãªãã®ã§ãããéãããçæéã®å®å
šæ§ããŒã¿ãããªããé·æéã®æ 人å®å
šæ§ããŒã¿ã¯ãªããããã«ããã®ã¯ã¯ãã³ã¯ããããŸã§ãããžã®äœ¿çšãæ¿èªãããããšã®ãªãããŸã£ããæ°ããmRNAã¯ã¯ãã³æè¡ã䜿çšããŠããŸããmRNAã¯äºå®äžãããã©ãã°ã§ãããã©ã®åäœãã©ãã ãã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãç£çãããã¯åãã£ãŠããŸããããŸããé
çºæ§ã®å¹æãçŸãããŸã§ã«æ°ã¶æããæ°å¹Žãããå¯èœæ§ããããŸããçŸåšè¡ãããŠããéãããåäŸåãã®èšåºè©Šéšã§ã¯ããŸãã§ã¯ãããæ·±å»ãªå¯äœçšãé€å€ããã«ã¯ãå
šãåäžè¶³ã§ããã
5 Covid-19ãã¯ã¯ãã³ãã¯ã¯ã¯ãã³ãšããŠåé¡ãããèŠä»¶ãæºãããŠããããå®éã¯éºäŒåæ²»çã§ããïŒæ·»ä»è³æ8ïŒãã¡ãªã¢ã -ãŠã§ãã¹ã¿ãŒèŸæžã¯ãCOVID-19 m-RNA泚å°ã®æåãå«ãããã«ããã¯ã¯ãã³ããšããçšèªã®å®çŸ©ãéãã«å€æŽããŸãããã¯ã¯ãã³ã®å®çŸ©ã¯ã2021幎2æ5æ¥ã®Covid-19泚å°ã«ããç¹ã«å€æŽãããŸããããã®èŠè«ã®å
±åç³è«è
ã§ããMike Yeadonå士ã¯ãCovid-19泚å°ããã¯ã¯ãã³ããšåŒã¶äž»åŒµã¯ãèšåºã®å
¬éæäœãšèåœè¡šç€ºã§ãããšäž»åŒµããŠããŸãã
æ²»çæ³ã§ããäºé²æ¥çš®ã§ã¯ãããŸãããææãé²ããã®ã§ã¯ãããŸãããææé²æ¢è£
眮ã§ããªããããªãã®äœãæ¯çŽ ãäœãããã«ä»åããæ段ã§ãããããããã°ããªãã®äœã¯ã©ãã«ãããŠæ¯çŽ ã«å¯ŸåŠããã®ã«æ
£ããã ãããšèšãããŠããŸããMRNAã¯çŽ°èã®æ©æ¢°ã䜿ã£ãŠããŠã€ã«ã¹ã®SPIKEã¿ã³ãã¯è³ªã«äŒŒãã¿ã³ãã¯è³ªãåæããããã®ã¿ã³ãã¯è³ªã¯ããŠã€ã«ã¹ãACE2å容äœãä»ããŠçŽ°èã«äŸµå
¥ãããšãã«äœ¿ããã®ã ããããŠããããã®ã¿ã³ãã¯è³ªã¯å
ç«ç³»ã«ãã£ãŠèå¥ãããå
ç«ç³»ã¯ãããã«å¯Ÿããæäœãäœããæ¬åœã«å¿é
ãªã®ã¯ããããã®ã¿ã³ãã¯è³ªãäœå
ãç¹ã«çæ®è
ºãªã©ACE2å容äœãå€ãååšããéšäœã«èç©ãããå¯èœæ§ãããããšã ããããå
ç«ç³»ããããã®ã¿ã³ãã¯è³ªãèç©ããŠããå Žæãæ»æããã°ãèªå·±å
ç«çŸæ£ãšãªãå¯èœæ§ããããŸãã
6 PCRæ€æ»
ãªãã¯ã¹ãã©ãŒã倧åŠã®Centre for Evidence-Based Medicineã®ã¬ãã¥ãŒïŒä»é²2ïŒã«ãããšãæšæºçãªPRCæ€æ»ã¯éåžžã«æ床ãé«ããæ»ãã ãŠã€ã«ã¹çŽ°èã®æçãæŸãäžããããšã§å€ãææçãæ€åºããããšãã§ãããšãããå
æ¥ãçç©è©Šæäžã®DNAãšRNAã®ååšãæ€åºããããã«éçºãããPCRã¯ãããŒãã«è³ãåè³ããçºæè
ã«ãªãŒã»ããªã¹ã§ãããç
æ°ã®èšºæãç®çãšããŠããªãã£ããšæèšããŠãããPCRã¯åã«ç¹å®ã®éºäŒç©è³ªã®ååšãæ€åºãããã®ã§ãããããã¯ææã瀺ãå Žåãããã°ç€ºããªãå Žåããããã«ãªãŒã»ããªã¹å士ãèšãããã«ãPCRæ³ã¯èª°ã«ã§ããã»ãšãã©äœã§ãèŠã€ããããšãã§ãããPCRæ€æ»ã§ã¯ãå¢å¹
ãµã€ã¯ã«ãçšããŠãŠã€ã«ã¹RNAãæ€åºããããµã³ãã«ã¯ååŠçã«å¢å¹
ãããæ€åºã§ãããŸã§RNAã®ã³ããŒãå¢ããããšãç¹°ãè¿ããããå¢å¹
ã®ããµã€ã¯ã«ãããšã«ããµã³ãã«äžã®ååæ°ã¯2åã«ãªããååãªãµã€ã¯ã«ãå®è¡ããã°ãã©ããªç©è³ªã§ãå¹çãã1ååãèŠã€ããããšãã§ããŸããã€ã³ã°ã©ã³ãå
¬è¡è¡çå±ïŒPHEïŒã®æ¹éã§ã¯ããµã€ã¯ã«ã®éŸå€ã25.6ååŸã«èšå®ããããšã確èªããŠãããããæ©æ¢°ããµã³ãã«ãæ€æ»ã®æ€åºéçãŸã§æã£ãŠããããã«25ãã35ãµã€ã¯ã«ïŒä»é²2aïŒä»¥äžå®è¡ããªããã°ãªããªãå Žåããµã³ãã«ã«ã¯èšåºçã«åé¡ãšãªãã»ã©ã®ãŠã€ã«ã¹ãå«ãŸããŠããªãããšã«ãªããŸãã
æ·»ä»è³æ2a)
ç§ãã¡ã¯ãæ
å ±å
¬éè«æ±ã«ããã40-45ã®ãµã€ã¯ã«ãå®æœãããŠãããšããæ
å ±ãåŸãïŒä»é²3ã3aã3bã3cïŒãPCRæ€æ»ã¯å
šãä¿¡é Œã§ããªãããšã«å ããçºçæ§ã®ãããšãã¬ã³ãªãã·ããå«ãã§ããã(ä»é²48)
7 ã³ãããã¯çç©å
µåšã§ãã - æ©èœç 究ã®ææ
äžåœã®ãŠã€ã«ã¹åŠè
ã§ãããª-ã¡ã³ã»ã€ã³ã¯ãåªããã¬ãªã»ããŒã³ã«ãŠã€ã«ã¹ã®èµ·æºã調æ»ããããäŸé Œãããäžåœã§covid-19ãç 究ããæåã®ç 究è
ã®äžäººã§ãããDr. Li-Meng YanãšåœŒå¥³ã®ããŒã ã¯ããã®æ°ããã³ãããŠã€ã«ã¹ããã³ãŠã¢ãªã®ã³ãããŠã€ã«ã¹ZC45ãšZXC21ããã³ãã¬ãŒããããã¯ããŒã³ãšããŠäœ¿ã£ãŠäœãããå®éšå®€ã®ç£ç©ã§ããããšäž»åŒµããå ±åæžãçºè¡šããŸããïŒä»é²4ïŒãå ±åæžã§ã¯ã"ZC45ãšZXC21ã¯2015幎7æãã2017幎2æã®éã«çºèŠãããåè¿°ã®è»äºç 究æã«ãã£ãŠåé¢ãããç¹åŸŽã¥ãããã "ãšãããŠããŸãããŸããéè»äºç 究æã§ããäžæµ·å
¬è¡è¡çèšåºã»ã³ã¿ãŒãã"SARS-CoV-2ãšRaTG13ãšã®éã§ã¯ãªãZC45/ZXC2ãšã®éã®çžåããå¯æ¥ãªç³»çµ±çé¢ä¿ãå ±åããNatureè«æãçºè¡šãããšããæ¯æ£ãã®ããã«ããã«ééãããã"ãšè¿°ã¹ãŠããŸãããŸãããã®å ±åæžã¯ãããã€ãã®åºçç©ãå±æããããšãéé£ããŠããŸãã
æ¿æ²»çãªå§åãå©ççžåã«ãã£ãŠãèªç¶èµ·æºèª¬ãšç°ãªãç 究çµæãçºè¡šããªãããã«ããããã§ããããèªç¶èµ·æºèª¬ãæ¯æããæ¢åã®ç§åŠåºçç©ã¯ãSARS-CoV-2ãš96ïŒ
ã®å¡©åºé
åã®åäžæ§ãå
±æããRaTG13ãšãã以åã«çºèŠãããã³ãŠã¢ãªã³ãããŠã€ã«ã¹ãšããåäžã®èšŒæ ã«å€§ããäŸåããŠãããã
8 ç±³åœåœç«è¡çç 究æïŒNIHïŒã¯ãã¢ã³ãœããŒã»ãã¡ãŠãå士ãç¹°ãè¿ãåŠå®ããŠããã«ãããããããäžåœã®æŠæŒ¢ç 究æã«ãããã³ãŠã¢ãªã³ãããŠã€ã«ã¹ã®æ©èœç²åŸç 究ã«å¯Ÿããè³éæäŸãèªããŠãããå
±åå
ã®ãžã§ãŒã ãºã»ã³ããŒè°å¡ã«å®ãŠãæçŽïŒä»é²5ïŒã®äžã§ãNIHã®Aã»ã¿ããã¯å¯æé·ã¯ãæŠæŒ¢ã®ç 究æã«ç±³åœã®è³éãæµãããšã³ãã«ã¹åçãããã®ä»äºã«ã€ããŠéææ§ãæ¬ ããŠãããšéé£ããŠããããšã³ãã«ã¹ãéå¶ããè±åœã®ç§åŠè
ããŒã¿ãŒã»ãã¹ã¶ãã¯ã¯ãå©æéã®æ¡ä»¶ãéµå®ããªãã£ããšã¿ããã¯ã«éé£ãããŠãããã€ãæè¿ãã2021幎11æã«ãã¡ãŠãã¯ãã€ã³ã¿ãŒã»ãããå
¥æããææžïŒä»é²6ïŒã«ãã³ãŠã¢ãªã®ã³ãããŠã€ã«ã¹ç 究ã®ããã«ãšã³ãã«ã¹åçã«äžããããå©æéã®è©³çŽ°ãèšèŒãããŠãããæ©èœç 究ã®å©çã«ã€ããŠåãã€ããŠãããšéé£ãããŠããã310äžãã«ã®å©æéã¯ã2014幎ãã2019幎ãŸã§ã®5幎éã«æž¡ã£ãŠæäžãããã2019幎ã«è³éãæŽæ°ãããåŸã2020幎4æã«ãã©ã³ãæ¿æš©ã«ãã£ãŠåæ¢ããããå©æéã¯ãã³ãŠã¢ãªã³ãããŠã€ã«ã¹ç 究ã®ããã«æŠæŒ¢ãŠã€ã«ã¹ç 究æã«599,000ãã«ãæ瀺ããã
9 ã€ã®ãªã¹ã®ã¢ã³ã¬ã¹ã»ãã«ã°ãªãŒã·ã¥ææãšãã«ãŠã§ãŒã®ç§åŠè
ãã«ã¬ãŒã»ãœãŒã¬ã³ã»ã³å士ã¯ããçç©ç©çåŠå£å ±ãã«å ±åæžãçºè¡šãïŒä»é²7ïŒãã³ãããŠã€ã«ã¹ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ã¯äººçºçã«æ¿å
¥ããããšæãããé
åããããšäž»åŒµããŠããŸãã圌ãã¯ã1幎åãããäžåœã«ãããã¬ãããšã³ãžãã¢ãªã³ã°ã®äžå¿ã®èšŒæ ããæã£ãŠãã-ããããåŠè
ãäž»èŠãªéèªããã¯ç¡èŠãããŠãã-ãšäž»åŒµããŠããŸãããã«ã°ãªãã·ã¥ã¯ãã³ãã³ã®ã»ã³ããžã§ãŒãžå€§åŠã®è
«çåŠææã§ããã蚺æãããæ£è
ãæ²»çããæ°ã¶æéè¬ã飲ãŸãªããŠãæžãããã«ããããã«ãåããŠå®çšçãªãHIVã¯ã¯ãã³ããéçºããç»æçãªæ¥çžŸã§ããç¥ãããŠãããæšå¹Žããã«ã°ãªãã·ã¥ãšã»ãŒã¬ã³ã»ã³ã¯ã¯ã¯ãã³ãäœãããã«COVID-19ã®ãµã³ãã«ãåæãããšããããŠã€ã«ã¹ã®äžã«å®éšå®€ã§ã®æäœã«ãã£ãŠã®ã¿çºçãåŸãããŠããŒã¯ãªæçŽããçºèŠããããã®çºèŠãçºè¡šããããšããããåœæã¯ãŠã€ã«ã¹ã¯ã³ãŠã¢ãªãªã©ã®åç©ããããã«èªç¶ã«ç§»ããã®ã ãšæå®ããŠããäž»èŠãªç§åŠéèªã«æåŠããããšèšããå
MI6é·å®ã®ãªãã£ãŒãã»ãã£ã¢ã©ãå¿ããã®ç§åŠè
ã®èª¬ã調æ»ãã¹ãã ãšå
¬èšããæã§ããããã®èãã¯ããã§ã€ã¯ã»ãã¥ãŒã¹ããšããŠéããããã
10 æ°Žé
žåã°ã©ãã§ã³
Andreas Noackå士ã¯ãã€ãã®ååŠè
ã§ãEUã§ãããã¯ã©ã¹ã®ã°ã©ãã§ã³å°é家ãççŽ å°é家ã掻æ§çåéã®å士å·ãæã¡ãå士è«æã§ã¯é
žåã°ã©ãã§ã³ãæ°Žé
žåã°ã©ãã§ã³ã«å€æããŠããŸããPablo Campraææã¯ã¢ã«ã¡ãªã¢å€§åŠã®åºèº«ã§ãAndreas Noackå士ãšäžç·ã«ãã³ãããã¯ã¯ãã³ãã«é
žåã°ã©ãã§ã³ãå«ãŸããŠãããã©ããããã€ã¯ãã©ãã³åå
æ³ïŒåšæ³¢æ°ã®ç 究ïŒã§èª¿ã¹ãŸãããäž¡å士ã«ãããšãã¯ã¯ãã³ã«ã¯é
žåã°ã©ãã§ã³ã¯å«ãŸããŠããªãããæ°Žé
žåã°ã©ãã§ã³ãå«ãŸããŠãããšã®ããšã2021幎11æ23æ¥ãã¢ã³ãã¬ã¢ã¹ã»ãã¢ãã¯å士ã¯ãæ°Žé
žåã°ã©ãã§ã³ãšã¯äœãã人äœã«æ³šå
¥ãããããæ§é äœããã¯ã¯ãã³ããåãã人ã®éèã®äžã§ãã«ããœãªã®åãã®ããã«äœçšããããšã説æãããããªãå
¬éãããæ¯ç©åŠè
ã¯ãè¡ç®¡ãåã£ãŠå
éšã§åºè¡æ»ããããããªæ§é ããããšã¯æ³åã§ããªãã®ã§ããã®ååçãªå€§ãããèãããšããããæ¢ãããšã¯ãªãã ãããšããããšã§ããã
11 2020幎11æ18æ¥ãã¢ã³ãã¬ã¢ã¹ã»ãã¢ãã¯å士ã¯ããŠãŒãã¥ãŒãã®ãã©ã€ãã¹ããªãŒã ãã§ã³ãŽã£ãã19ãã¯ã¯ãã³ãã®å±éºæ§ãè«ããŠãããšãããæŠè£
ãããã€ãèŠå¯ã«ã«ã¡ã©ã§é®æãããŸããïŒä»é²41ïŒã2021幎11æ26æ¥ãé
žåã°ã©ãã§ã³ãšæ°Žé
žåã°ã©ãã§ã³ã«ã€ããŠã®ææ°ãããªïŒä»é²42ïŒãå
¬éãããããæ°æéåŸã圌ã¯è¥²æãã殺害ãããã
12 ç§ãã¡ã¯ãCovid-19ãã¯ã¯ãã³ãã«æ°Žé
žåã°ã©ãã§ã³ãå«ãŸããŠããããšãšãã¢ã³ãã¬ã¢ã¹ã»ãã¢ãã¯å士ã®æ殺ã«ã€ããŠãå®å
šãªèª¿æ»ãè¡ãããšãèŠè«ããã
13 ã³ãããã®æ°åãèªåŒµãããŠãã
ã³ããã19ã®çäŸæ°ã¯ãPCRæ€æ»ã®äžæ£ç¢ºããšä¿¡é Œæ§ã®äœãã®ããã«äººçºçã«èªåŒµãããŠãããè±åœã«ãããã³ããã19ã®æ»äº¡è
æ°ã¯ãã³ããã19æ€æ»éœæ§ïŒäžæ£ç¢ºã§ä¿¡é Œæ§ã®äœãPRCæ€æ»ã§ç¢ºèªïŒåŸ28æ¥ä»¥å
ã«äœããã®çç±ã§æ»äº¡ããå Žåãã³ãããæ»äº¡ãšèšé²ããããšããäºå®ã®ããã«ã倧èŠæš¡ã«äººçºçã«èšåŒµãããŠããããããã®æ»äº¡ã¯ãã³ããã19ãäºå®äžã®æ»å ã§ãããã©ããã«ããããããã³ããã19ãšããŠèšé²ãããŠããã®ã§ãã
14 æ
å ±å
¬éè«æ±ïŒä»é²43ïŒã«ãããšã2020幎3æãã6æã«ãããŠãã€ã³ã°ã©ã³ããšãŠã§ãŒã«ãºã§ãæ¢åŸçã®ãªãCovid-19é¢é£ã®æ»äº¡è
æ°ã¯ã4,476人ã§ããããšãããã£ãã
(æ·»ä»è³æ43)
15 ããããåæéã®Covid-19ã®æ»äº¡è
æ°ã¯49,607人ãšèšé²ãããŠããïŒè³æ44ïŒã
(æ·»ä»è³æ44)
16 ç§ãã¡ã¯ãã³ããã19ã®çµ±èšã人çºçã«æ¡å€§ãããããäžã€ã®æ¹æ³ã¯ãäžè¬çãªã€ã³ãã«ãšã³ã¶ãèºçããã®ä»ã®åŒåžåšææçãã³ããã19ãšããŠãåãã©ã³ãåãããããšã§ãããšæå±ããŠããŸããããã¯ãã§ã©ãŒå€§åŠã®çç©çµ±èšåŠãç«åŠãç 究èšèšã®å
責任è
ã§ããç«åŠè
ã®ã¯ããŒãã»ãŠã£ããŠã¹ããŒã¯ããïŒã€ã³ãã«ãšã³ã¶ã®çç¶ãšééãããïŒã³ãããã®çç¶ããããªããSARS RNAã®æ€æ»ãåããŠããªããæšå®ã³ããããã«ããŽãªãŒã«å«ãŸããã€ã³ãã«ãšã³ã¶æ£è
ãããªãå€ããããããªãããšäž»åŒµããŠããããããã®æ£è
ã¯ããã€ã³ãã«ãšã³ã¶ã«ææããŠããéã錻ã®äžã«SARS RNAãæ®ã£ãŠããå¯èœæ§ãããããã®å Žåã¯ã€ã³ãã«ãšã³ã¶ãCovidã§ãããšã確èªããããã ããããšåœŒã¯äž»åŒµããŠããã
17 ONSã®ããŒã¿ïŒä»é²45ïŒã«ãããšã2018幎ã®ã€ã³ãã«ãšã³ã¶ããã³èºçã«ããæ»äº¡è
æ°ã¯29,516人ã2019幎ã¯26,398人ã§ãã£ãããããã2020幎ã®ã€ã³ãã«ãšã³ã¶ã«ããæ»äº¡è
æ°ã¯ããã394人ãèºçã¯13,619人ãšèšé²ãããŠããïŒä»é²46ïŒã
x 45)
(ã¢ãã³ãã£
18 æ¬èŠè«ã®å
±åç³è«è
ã§ãããžã§ã³ã»ãªã«ãŒããŒã¯ããã«ãã³ããŒã³ãºã§èªåã®è¬å瀟ãçµå¶ããè¬åå±ã§ããã圌ã¯ãè¬åå±ãšããŠãCovidã®æ»äº¡æ°ãæå³çã«èšããŸãã倧èŠæš¡ãªåªåãèŠãããšèšŒèšããŠããŸãïŒAppendix 47ïŒãããæ£è
ãè³åäž
(æ·»ä»è³æ46)
ã®ç ç²è
ããããŠäžäººã®èœ¢ãããç·ã§ãããããã®æ»å ã«Covidãå«ãŸããŠããã
蚌ææžãã
18a ç§ãã¡ã¯ãã³ããçäŸãšã³ããæ»äº¡ã®èåœã®è¡šç€ºã¯ãå®å
šãª
ã調æ»ããã
19 ãã¹ã¯ã®éå¹ææ§
äžçä¿å¥æ©é¢ïŒWHOïŒã¯ãéç
人ãå®ãããã®ãã¹ã¯ã®æçšæ§ã«ã€ããŠãå©çšã§ãã蚌æ ããªãããšãèªããŠããïŒæ·»ä»è³æ9ïŒãäœé
žçŽ ãšé«çé
žã«å ããŠããã§ã€ã¹ãã¹ã¯ãéããŠåŒåžãããšããã§ã€ã¹ãã¹ã¯ã®å
åŽãšå€åŽã®å±€ã«çŽ°èãšçŽ°èã®æåãæ®çããããããã®æ害æåãç¹°ãè¿ãåžå
¥ããããšã§ãèªå·±æ±æã«ã€ãªããããŸãããã¹ã¯è¶ãã®åŒåžã¯ãå£ãšãã¹ã¯ã®éã®æž©åºŠã湿床ãäžæããããã¹ã¯ã®çŽ æããææ¯ãªç²åãæŸåºãããããã系統çãªæç®èª¿æ»ã«ãããšããã¹ã¯ã®ãšã¢ããŸã«æ±æã¬ãã«ã¯ã13ïœ202,549çš®é¡ã®ãŠã€ã«ã¹ãå«ããšæšå®ãããŠããŸããé«æ¿åºŠã®çŽ°èãšææ¯ç²åãå«ãæ±æ空æ°ãäœé
žçŽ ãšé«äºé
žåççŽ ãšãšãã«ååžå
¥ãããšã身äœã®æåžžæ§ãæãªãããèªå·±æ¯æ§ãšå
ç«æå¶ãåŒãèµ·ããããã(ä»é²10ïŒ
20 代æ¿çæ³
Peter McCulloughå士ã¯ãå
ç§å»ãå¿èå°éå»ããããµã¹AïŒMå»ç§å€§åŠææã§ãããã€ã©ãŒå€§åŠã§åŠå£«å·ãååŸåŸããã©ã¹ã®ãããµã¹å€§åŠãµãŠã¹ãŠã§ã¹ã¿ã³å»åŠéšãåæ¥ããã¢ã«ãã¡ã»ãªã¡ã¬ã»ã¢ã«ãã¡ãšããŠå»åŠå士å·ãååŸããããŸããã·ã¢ãã«ã®ã¯ã·ã³ãã³å€§åŠã§å
ç§ã®ã¬ãžãã³ããããŠã£ãªã¢ã ã»ããŒã¢ã³ãç
é¢ã§å¿èç
åŠã®ãã§ããŒã·ããïŒããŒããã§ããŒãå«ãïŒãããã·ã¬ã³å€§åŠã§å
¬è¡è¡çã®ä¿®å£«å·ãååŸããã
21 ããããã·ã¯ãããã³
COVID-19ã®äžã§æãåºãç 究ãããå©çšãããŠããè¬å€ãåºæ¬çã«3ã€ã®äœçšæ©åºãããããšã³ããœãŒã ãä»ãããŠã€ã«ã¹ã®äŸµå
¥ãæãããäºéã€ãªããã©ã¢ãšããŠåããäºéã¯RNAäŸåæ§ããªã¡ã©ãŒãŒãé»å®³ããåããããŸãããããŠæåŸã«ãæççäœçšã§ãã现èå
šäœã®ãããã£ãŒã«ãå€åãããççãæããããšãã§ããã®ã§ãã259ã®æ¯æçè©Šéšã385,000人ã®æ£è
ãããããã·ã¯ãããã³ã¯ãç§ãèšãããã«ãCOVID-19æ²»çã®äž»è»žã§ããå€æ¥æ£è
ã察象ãšãã倧èŠæš¡ãªè©Šéšã§ããã¶ãŒãæ¯
ããã¯ãå€æ¥èšºçã§ã®å
¥é¢ãšæ»äº¡ã50ïŒ
æžå°ããããšãæå³ããŸããã€ã©ã³ã§è¡ãããéåžžã«å€§èŠæš¡ãªç 究ã§ã¯ãããã«ããããã«ã28,000人ããé«ãªã¹ã¯æ£è
ã®çŽ25ïŒ
ã«ããããã·ã¯ãããã³ïŒä»ã®è¬ã®çæã³ãŒã¹ã§æ²»çããå
¥é¢ãšæ»äº¡ã30ïŒ
æžå°ãããŠããŸãïŒæ·»ä»è³æ15ïŒã
22 ã€ãã«ã¡ã¯ãã³
ãŠã€ã«ã¹ã®æ žãžã®äŸµå
¥ãé»å®³ããããäžã€ã®è¬å€ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã«å¯ŸããŠãäœããã®ç¹æ§ãæããŠããŸããã€ãã«ã¡ã¯ãã³ã«ã€ããŠã¯60ã®è©Šéšããããããããã·ã¯ãããã³ã«æ¯ã¹ãã°ã¯ããã«å°ãªãæ
å ±éã§ãããããã§ãããªãã®éã§ããã€ãã«ã¡ã¯ãã³ã¯å
¥é¢ãå€æ¥ãšãã«è¯å¥œãªãã¶ãŒãæ¯ã瀺ããæ»äº¡çãçŽ70ïŒ
æžå°ãããããšãããããŸããã(æ·»ä»è³æ16)
23 ãã¡ããã©ãã«
å
šäœã§5ã«åœã§è²©å£²ãããŠãããçµå£ã®Remdesivirã®ãããªãã®ã§ããã¬ã ãã·ãã«ã¯çŸåšãæ¥æ¬ã§ã¯COVID-19ã®åå ãŠã€ã«ã¹ã§ããSARS-CoV-2ã«ææããæ£è
ããã®æ²»çè¬ãšããŠæ¿èªãããŠããŸããæ¥æ¬ä»¥å€ã§ã¯ãã¬ã ãã·ãã«ã¯æ²»éšè¬ã§ãããæªæ¿èªè¬ã§ãã
ãã€ãªè£œè¬äŒç€Ÿã®ãªã¢ãã»ãµã€ãšã³ã·ãºãéçºãããã®åºåæãŠã€ã«ã¹è¬ã¯ãCOVID-19ã§å
¥é¢ããäžæ°éææã確èªãããæ人ã«ãããŠãå埩ãŸã§ã®æéãççž®ããäžã§ãã©ã»ãããåªããŠãããš5æã®New England Journal of Medicineèªã«å ±åãããŠããŸãïŒå¥æ·»17ïŒã
24 å¯è
ç®è³ªã¹ããã€ã
å
¥é¢æ²»çã®äž»è»žãšãªããã®ã§ããã¡ã¿ã¢ããªã·ã¹ã§ã¯æ»äº¡çã30ïŒ
äœäžããããšã瀺åãããŠãããåžå
¥ãããœããïŒç±³åœã§ã¯ãã«ãã³ãŒããšããŠç¥ãããŠããïŒã¯ãStoic TrialãšåŒã°ããç¡äœçºåè©Šéšã§æäžãããããããœããã®åžå
¥æäžã§å
¥é¢ã87ïŒ
æžå°ãããçµå£ãåžå
¥ã¹ããã€ããšãã«ããžãã£ããªããŒã¿ãåºãŠããããã§ãïŒæ·»ä»è³æ18ïŒã
25 ã³ã«ããã³ïŒãªãã©ãã«ïŒ
ã³ã«ããã³ã¯æççè¬ã§ãããæ倧ãæé«å質ã®ç¡äœçºããã¹ãã¯ãã£ãäºéç²æ€ãã©ã»ã察ç
§è©Šéšã§ãããããã¯ã¢ã³ããªãªãŒã«å¿èç 究æã§èª¿æŽããããã®ã§ãããçç¶ã®ããCOVID-19ã®å€æ¥æ£è
4,000人以äžã察象ãšããéœæ§ã確èªãããæ£è
ã®ãã¡ãå
¥é¢ãšæ»äº¡ã25ïŒ
æžå°ããïŒä»é²19ïŒã
26
ã¯ã¬ãŒãxãšã€ãã³ã201ã®ã·ããªãª
2018幎5æãWEFã¯ãžã§ã³ãºã»ãããã³ã¹ãšææºãããã¯ã¬ãŒãXããšåä»ããããæ¶ç©ºã®ãã³ãããã¯ã®ã·ãã¥ã¬ãŒã·ã§ã³ãè¡ãïŒä»é²12ïŒãäžäžç Žæ»
çãªãã³ãããã¯ã«çŽé¢ããå Žåã«äžçãã©ã®çšåºŠã®åããããã®ããèŠãŠã¿ãããããã1幎äœããWEFã¯åã³ãžã§ã³ãºã»ãããã³ã¹ãšçµã¿ããã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£ãšãšãã«ã2019幎10æã«ãã€ãã³ã201ããšåŒã°ããå¥ã®ãã³ãããã¯ã®æŒç¿ãè¡ã£ãïŒä»é²13ïŒãã©ã¡ãã®ã·ãã¥ã¬ãŒã·ã§ã³ããäžçã¯äžççãªãã³ãããã¯ã«å¯ŸããŠæºåãã§ããŠããªããšããçµè«ã«éãããã³ãããŠã€ã«ã¹ã®çºçãå
·äœçã«ã·ãã¥ã¬ãŒã·ã§ã³ãããã€ãã³ã201ãã®çµäºããæ°ã«æåŸãäžçä¿å¥æ©é¢ïŒWHOïŒã¯2020幎3æ11æ¥ã«ã³ãããŠã€ã«ã¹ããã³ãããã¯ç¶æ
ã«éãããšå
¬åŒã«å®£èšããŸããã
"次ã®æ·±å»ãªãã³ãããã¯ã¯ã倧ããªç
æ°ã人åœã®æ倱ãåŒãèµ·ããã ãã§ãªããäžççãªåœ±é¿ãèŠãã¿ã«å€§ããè²¢ç®ãããçµæžçã»ç€ŸäŒçã«é£éããçµæãåŒãèµ·ããå¯èœæ§ããããŸã" - ã€ãã³ã201ãã³ãããã¯ã·ãã¥ã¬ãŒã·ã§ã³ïŒ2019幎10æïŒã
ãã以æ¥ããã¯ã¬ãŒãXãããã€ãã³ã201ãã®ã·ãã¥ã¬ãŒã·ã§ã³ã§åãäžããããã次ã®ãããªã»ãŒãã¹ãŠã®ã·ããªãªãç»å Žããããã«ãªããŸããã
äžçäžã®æ¿åºãããã¯ããŠã³ãå®æœ
å€ãã®ç£æ¥ã®åŽ©å£
æ¿åºãšåžæ°ã®éã«åºããäžä¿¡æ
ãã€ãªã¡ããªã¯ã¹ç£èŠæè¡ã®æ®å
èª€å ±å¯Ÿçã«åãåãããœãŒã·ã£ã«ã¡ãã£ã¢æ€é²
æš©åšãããæ
å ±æºã§ã³ãã¥ãã±ãŒã·ã§ã³ã»ãã£ã³ãã«ãåãå°œãããããšããé¡æ
äžççãªå人çšä¿è·å
·ã®äžè¶³
åœéçãªãµãã©ã€ãã§ãŒã³ã®åŽ©å£
倧é倱æ¥
è¡é ã§ã®æŽå
27
27a
28 2020幎åã°ãŸã§ã«æªå€¢ã®ã·ããªãªãå®å
šã«çŸå®åããåŸã2021幎6æã«WEFåµèšè
ããä»ããã°ã¬ãŒããªã»ããã®æããšå®£èšãã
29 ã¯ã¬ãŒã X ãšã€ãã³ã 201 ãäºèšçã§ãã£ãããšãå€æããã®ã¯ãWEF ãšããŒãããŒã®åŽã§çŽç²ã«åªããäºæž¬ãèšç»ãã¢ããªã³ã°ã§ããããšã¯ãä¿¡ããããªãã»ã©å¯èœæ§ãäœãããšãç§ãã¡ã¯æå±ããã
30 ã¢ãžã§ã³ã21/30ãšã°ã¬ãŒããªã»ããã¢ãžã§ã³ã
ããã³ãããã¯ã¯ãããå¥åº·ã§ãããå
¬å¹³ã§ãããè±ããªæªæ¥ãåµé ããããã«ãç§ãã¡ã®äžçãæ¯ãè¿ããåæ§ç¯ãããªã»ããããããã®ãçšã§çãæ©äŒã®çªã瀺ããŠããŸãã-ã¯ã©ãŠã¹ã»ã·ã¥ã¯ããäžççµæžãã©ãŒã©ã
31 ãããããã°ã¬ãŒããªã»ãããã¯ãå°çäžã®èª°ãããæè²ãã瀟äŒå¥çŽãåŽåæ¡ä»¶ã«è³ããŸã§ã瀟äŒãšçµæžã®ããããåŽé¢ãèŠçŽãããã«å
±åãã€è¿
éã«è¡åãããããšã«åæããã°ããããå®å
šã§ãããå¹³çã§ãããå®å®ããäžçããç¯ãããšãçŽæãããã®ã§ãã(ãããããã®ãããªæ°ããäžç秩åºã®ããã®å
æ¬çãªèšç»ãå
·äœåããããã«ã¯ã瀟äŒã®æ ¹åºã«è¡æãäžãããããªäžççãªå±æ©ãããããäœããããã®ã§ãããäžå¹žãªå¶ç¶ã§ãããçºçããªããã°ãªããªãã£ãã ããã
32 ãžã§ã³ãºã»ãããã³ã¹å¥åº·å®å
šä¿éã»ã³ã¿ãŒãäžççµæžãã©ãŒã©ã ããã«ã»ã¢ã³ãã»ã¡ãªã³ãã»ã²ã€ã財å£ã¯ããã³ãããã¯çºçæã«æ¿åºãåœéæ©é¢ãã°ããŒãã«äŒæ¥ãåŸãã¹ã7ã€ã®å§åãå
±åã§æåºããïŒæ·»ä»è³æ14ïŒãã€ãã³ã201ã®æèšã§ã¯ãå®æ°ã®ååäœå¶ã®åŒ·åãæ±ããäžæ¹ã§ãWHOãäžçéè¡ãåœéé貚åºéãåœéèªç©ºééæ©é¢ãªã©ãéžæã§éžã°ããããã§ã¯ãªãã°ããŒãã«ãªæ©é¢ãšããŒãããŒã·ããã確ç«ããäžå
çã«å¯Ÿå¿ããããšã®éèŠæ§ã匷調ããŠãããæèšã®ã²ãšã€ã¯ãæ¿åºããœãŒã·ã£ã«ã¡ãã£ã¢äŒæ¥ãå ±éæ©é¢ãšææºããã³ã³ãã³ããæ€é²ããæ
å ±ã®æµããã³ã³ãããŒã«ããããšãæ±ããŠããã
33 å ±åæžã«ãããš
æ¿åºã¯ãäŒçµ±çãªã¡ãã£ã¢äŒæ¥ããœãŒã·ã£ã«ã¡ãã£ã¢äŒæ¥ãšææºããèª€å ±ã«å¯Ÿæããããã®æ©æãªã¢ãããŒããç 究ã»éçºããå¿
èŠãããããååœã®å
¬è¡è¡çæ©é¢ã¯ãWHOãšç·å¯ã«é£æºããäžè²«ããå¥åº·ã¡ãã»ãŒãžãè¿
éã«éçºã»çºè¡šããèœåãæ§ç¯ããå¿
èŠããããã¡ãã£ã¢äŒæ¥ã¯ãæš©åšããã¡ãã»ãŒãžãåªå
ãããåœãã®ã¡ãã»ãŒãžãæå¶ããããããæè¡ã®æŽ»çšãå«ããŠåªåããå¿
èŠãããã
34 æ€é²
2020幎ãéããŠãTwitterãFacebookãYouTubeã¯ãã€ãã³ã201ãæšå¥šããŠããããã«ãæ¹éãšããŠäžçä¿å¥æ©é¢ïŒWHOïŒã®å§åã«åããã³ãããŠã€ã«ã¹é¢é£æ
å ±ãæ€é²ãæå¶ããã©ã°ç«ãŠããŠããã倧æãã€ãã¯äŒæ¥ã¯ã2020幎ã®ç±³åœå€§çµ±é éžæã®éã«ããåãã³ã³ãã³ã匟å§æŠè¡ãå±éããŸãããéžæã®å®å
šæ§ã«çåãåããã³ã³ãã³ãã«ãä¿äºäžãã®ã¯ã¬ãŒã ãæ·»ä»ããã®ã§ããè±åœæ¿åºãäžçäžã®æ¿åºã¯ãè¡šçŸã®èªç±ãšæ
å ±ãžã®ã¢ã¯ã»ã¹ãåãç· ãŸãããã«ããã³ãããã¯ããå©çšããŠããã®ã ãCovid-19ã®çºçåœåãããæ¿æ²»çé
æ
®ãå
¬è¡è¡çãè¡šçŸã®èªç±ã«é¢ããæžå¿µãšè¡çªããŠãããåœå±ã¯åæ³çãªãŠã§ããµã€ãããããã¯ããäžèŠãªã³ã³ãã³ãã®åé€ãåœããŠãããåœå±ã¯ãããå€ãã®ã«ããŽãªãŒã®ãªã³ã©ã€ã³è¡šçŸãç¯çœªåããæ¿åºã®ããã©ãŒãã³ã¹ã«ã€ããŠå
¬ã«çºèšãããžã£ãŒããªã¹ãã掻å家ãäŒå¡ãé®æããããšã§ãããããèŠå¶ã匷åããŠããŸãããäžå©ãªå¥åº·çµ±èšãæ¹å€çãªå ±åããã®ä»ã®COVID- 19ã³ã³ãã³ããæå§ããããã«ãè±åœæ¿åºã¯ãŠã§ããµã€ãããããã¯ãããããŠãŒã¶ãŒããœãŒã·ã£ã«ã¡ãã£ã¢ã»ãã©ãããã©ãŒã ããªã³ã©ã€ã³ã¢ãŠãã¬ããã«æ
å ±ã®åé€ã匷èŠããŠãããå»åž«ãæ£è
ãæ²»çããèªç±ã«å¯ŸããåäŸã®ãªãæ»æããããRNAã¯ã¯ãã³ã®çºæè
ã§ãããããŒãã»ãããŒã³å士ã¯ãã³ãã泚å°ã«å察ãè¡šæããããã«ããã¹ãŠã®ãœãŒã·ã£ã«ã¡ãã£ã¢ã§ãã©ãããã©ãŒã ã解é€ãããŸãããäžéšã®åŠè¡èªã¯ãã€ãã«ã¡ã¯ãã³ãããããã·ã¯ãããã³ã®ãããªè¬å€ã®æå¹æ§ã瀺ãç 究ã®åºçã劚害ããŠããŸããã³ããã19ãšã³ããã19ãã¯ã¯ãã³ãã«é¢ããWHOã®ã·ããªãªã«ç°è°ãå±ããå»åž«ãç§åŠè
ã«å¯Ÿããäžå·ãã£ã³ããŒã³ãå±éãããŠããã®ã§ããç§ãã¡ã¯ãæ¿åºãšåœéçãªNGOãå»çå°é家ãæ¯é
ããŠããç¶æ³ã«ããã®ã§ãã
1930幎代ã®ãã€ããšã®é¡äŒŒæ§
34a ãã€ãã®ããã³ãŒã¹ãã®çåè
ã®äžã«ã¯ãã³ãããã®èŠå¶ãšããã³ãŒã¹ãã®å§ãŸããšã®éã«åŒ·ãé¡äŒŒæ§ã瀺ã人ãäœäººãããŸãã欧å·å»çæ©é¢ïŒEMAïŒãè±åœå»è¬åå»ç補åèŠå¶åºïŒMHRAïŒããªãŒã¹ãã©ãªã¢ä¿å¥èŠå¶åºïŒAHPRAïŒããªãŒã¹ãã©ãªã¢å»è¬ååºïŒTGAïŒããã¥ãŒãžãŒã©ã³ãã®Medsafeãã«ããã®å»çèŠå¶æ©é¢é£åïŒFMRACïŒã«éã£ãå
¬éæžç°¡ïŒä»é²50ïŒã«ã¯ã次ã®ããã«æžãããŠããŸãã
ãç§ãã¡ã¯ã第äºæ¬¡äžç倧æŠäžã«äººé¡ã«å¯ŸããŠè¡ãããæ®èè¡çºã®çåè
ã§ãããè¯å¿ã«åŸããªããã°ãªããªããšæããŠããŸãã...ç§ãã¡ã®ç®ã®åã§ãããã«å€§èŠæš¡ãªããã³ãŒã¹ããè¡ãããŠãããç§ãã¡ã¯ããã®éªæªãªå»çå®éšãæ¢ããããšãæ±ããŸãã
ããä»ããã«ã§ãããã¯ãã¥ã«ã³ãã«ã¯æ³ãé©çšãã¹ãå»çå®éšã§ãã"(ã©ãã»ãã¬ã«ã»ãã³ãã©ãŒããã¬ãŒã»ã·ã£ããªãŒã«ããœãªã³ã»ã·ã£ãã©ãããã·ã£ã»ãªã¬ã«ãã¢ãªãŒã»ã¯ãªã¹ããŒã³ã»ã)
34b ã©ã€ããŒã»ãã¥ãšã«ããå士ãšã®ã€ã³ã¿ãã¥ãŒïŒä»é²51ïŒã§ãããã³ãŒã¹ãã®çåè
ãŽã§ã©ã»ã·ã£ã©ãã¯ãããã¹ã»ãã€ãã§ã®çµéšãããšã«ãä»æ¥ã®äžçã§èµ·ãã£ãŠããããšã«ã€ããŠèªåã®èŠè§£ãè¿°ã¹ãŠããŸããã€ã³ã¿ãã¥ãŒã®äžã§ã圌女ã¯æ¬¡ã®ããã«èªã£ãŠããã
34c ãããã¹æ¿æš©ã®ããšã§ã¯ãé埳çèŠç¯ã¯çµç¹çã«æ¹æ®ºãããŸãããå»åŠã®å°é家ãšå¶åºŠã¯æ ¹æ¬çã«å€ãããåŠè¡ç§åŠãè»ãç£æ¥ãèšåºå»åŠã¯ãçŸåšãšåãããã«å¯æ¥ã«çµ¡ã¿åã£ãŠããŸãããããã¹ã®äœå¶ã¯ãå
¬è¡è¡çã®åã®äžã«ç€ŸäŒçè¯å¿ãç Žå£ãããå人ãšéå±€ã«å¯Ÿãã䟵害ãå¶åºŠåããããåªçåŠã«åºã¥ãå
¬è¡è¡çæ¿çããå人ã®å©çã«å¯Ÿããå»åž«ã®çŠç¹ã«åã£ãŠä»£ãã£ãã[ãã€ãã®å»ççãšå»çå¶åºŠã¯å€è³ªããã匷å¶çãªå
¬è¡è¡çæ¿çã¯ãå人ã®åžæ°æš©ãšäººæš©ã䟵害ãããæ¿çã匷å¶ããããã«ç¯çœªçãªæ¹æ³ã䜿ããããããã¹ã®ãããã¬ã³ãã¯ãäŒæç
ã®ææãå©çšããŠããŠãã€äººãç
æ°ã®è延è
ãšããŠãå
¬è¡è¡çã«å¯Ÿããè
åšãšããŠæªè
ã«ä»ç«ãŠäžããŸãã....ææãšãããã¬ã³ãã¯ãããã¹ã倧éè殺ãè¡ãããã«äœ¿çšããå¿ççæŠåšã§ãããä»æ¥ããã€ãåœæ°ããªãç«ã¡äžãããªãã£ãã®ããææãæ£ããããšããããªãããã«ããŠããã®ã ãšç解ãå§ããŠãã人ãããã ãããå»çå¶åºŠã¯ããã¡ã·ã¹ãç¬è£ãšå€§éè殺ãžã®å€§ããªéè¡ã§ãããæ¿åºã®æ瀺ãå»çä»å
¥ããããã¯ç§ãã¡ã®å°å³ãšèªç±ãæãªããã®ã§ããããã³ãŒã¹ãã®å³ããæèšã¯ãå»åž«ãæ¿åºãšæãçµã³ãå人ã«å®³ãäžããªããšããå人çãè·æ¥çãèšåºçãªçŽæããéžè±ãããšãã¯ãã€ã§ããå»çã¯çããšäººéçè·æ¥ãã殺人è£
眮ã«å€è³ªãåŸããšããããšã§ããããã³ãŒã¹ããä»ã®å€§éè殺ãšç°ãªãã®ã¯ãå»åŠçã®æš©åšãã€ãŸãå»åŠçå
šäœã極ããŠéèŠãªåœ¹å²ãæããããšããããšã§ãã殺人ããã»ã¹ã®ãããã段éããåŠè¡çãå°éçãªå»åŠçã®æš©åšã«ãã£ãŠæ¿èªãããã®ã§ãããå»åŠå士ãæš©åšããå»åŠäŒãå»åŠæ©é¢ã¯ã幌å
è殺ãæ°é人ã®å€§é殺æ®ã«æ£åœæ§ã®ç®ã被ããã®ã§ãããT4ã¯ãæŽå²äžæåã®å·¥æ¥åãããå»ç殺人ãããžã§ã¯ãã§ãã£ããæåã®ç ç²è
ã¯ãé害ãæã£ããã€ãã®å¹Œå
ãš3æ³ä»¥äžã®åäŸãã¡ã ã£ã...ã次ã«ç²Ÿç¥é害è
ããããŠè人ããŒã ã®è人ãç ç²ã«ãªã£ãããã®æ®ºäººäœæŠã¯çè·¯æŽç¶ãšããŠãããéåžžã«æ
éã«æé ã«æ²¿ã£ãŠè¡ãããã"
B.ãã¥ã«ã³ãã«ã¯ã»ã³ãŒã
35 第äºæ¬¡äžç倧æŠäžã«æãããå»åŠå®éšãè¡ã£ãããã¹ã®ç¯çœªè
ãè£ãããU.S.A. vs. Karl Brandt, et al.ïŒãã¥ã«ã³ãã«ã¯å»åž«è£å€ïŒãã®æ³åŸã«åºã¥ãå»åŠå«çèŠç¯ããã®ãã¥ã«ã³ãã«ã¯ç¶±é ã¯ãåŸã«ãã«ã·ã³ã宣èšïŒ1965幎ïŒã®åºç€ãšãªããäžçå»åž«äŒããã³éæ¥å»ã¯ãå»çãæäŸããéã«ã¯ïŒåã
ã®ïŒæ£è
ã®æåã®å©çã®ããã«è¡åãããããšã矩åã¥ããããŠããã
36 ããŒãèŠçšã®ç¬¬ 21 æ¡ã¯ãICC ãåèã«ã§ããæ³çæ ¹æ ãå®ããŠãããåèŠçŽã¯ãåœéæ¡çŽãåœéæ
£ç¿ãããã³ææåœã«ãã£ãŠèªããããæ³ã®äžè¬ååã® 3 ã€ã®äž»èŠãªåœéæ³ ã®æºæ³ãå®çŸ©ããŠããããã®3ã€ã®æ³æºã¯åçã®äŸ¡å€ãæã¡ããããã®éã«åºåã¯ãªããšèªèãããŠãããæ³ä»€ã«ããã°ãæ³ã®èŠåã決å®ããããã®è£å©çãªæ段ã¯ãåžæ³å€æãšåŠè¡çãªèäœç©ã§ãããããã®åæãããæ
å ±æºä»¥å€ã«ãã宣èšãçä¿ã®ãããªäžæ¹çãªè¡çºã«ãã£ãŠåœéæ³äžã®èŠåãäœãããšãã§ããïŒShabas William, An Introduction to the International Criminal Court, 155, (2017))
36a æã
ã¯ããã¥ã«ã³ãã«ã¯ç¶±é ãããŒãèŠçšç¬¬21æ¡1é
ïŒbïŒã«ããåœéæ³ã®åºå
žãšããŠé©æ Œã§ããããšãè£å€æã«æåºããŸãã21æ¡3é
ã¯ãæ³åŸã®é©çšãšè§£éã¯ãåœéçã«èªãããã人暩ãšäžèŽããªããã°ãªããªãããšè¿°ã¹ãŠãããç§ãã¡ã¯ããã®ãå»åž«ã®è£å€äŸããããã®èŠè«ã®ç®çã®ããã«åŒãåºãããªããã°ãªããªãåäŸã確ç«ãããã¥ã«ã³ãã«ã¯æ³å
žããŠã¹ã»ã³ãŒã²ã³ã¹ååã®äžã§åœéæ³ã®æºãšããŠé©æ Œã§ãããšããæŠå¿µãæ€èšã®ããã«æåºããã
37 æ
£ç¿çïŒjus cogensïŒåœéæ³ã®èŠçŽ ã«ã¯ã以äžã®ãããªãã®ãããã
åæ§ã®åœéçè¡çºãåœå®¶ã«ãã£ãŠé·æã«ããã£ãŠåºãç¹°ãè¿ãããããšïŒåœå®¶æ
£è¡ïŒã
ãã®è¡çºã矩åæããçãããã®ã§ãªããã°ãªããªããšããèŠä»¶ïŒopinio jurisïŒãããã³
ãã®è¡çºãçžåœæ°ã®åœã«ãã£ãŠè¡ãããçžåœæ°ã®åœã«ãã£ãŠæåŠãããªãããšã
ã®åœãããã
38 1950 幎ãåœéæ³å§å¡äŒã¯æ
£ç¿åœéæ³ã®èšŒæ ãšããŠãæ¡çŽãåœå
è£å€æãåœéè£å€ã®å€æ±ºãåœå
æ³ ãæããŠããã
å€äº€ææžãååœã®æ³åŸé¡§åã®æèŠãåœéæ©é¢ã®å®åïŒãåœéæ³å§å¡äŒã®ç·äŒãžã®å ±åïŒç¬¬ 2 éšïŒãïŒãåœéæ³å§å¡äŒã®ç·äŒãžã®å ±åïŒç¬¬2éšïŒïŒåœéæ
£ç¿æ³ã®èšŒæ ããã容æã«å©çšã§ããããã«ããæ¹æ³ãšæ段ã [1950] 2 Y.B. Int'l. Comm'n 367, ILC Doc.A/1316).
39 i. å®è·µèŠä»¶ - ç§ãã¡ã¯ããã®èŠä»¶ã¯ãåœéçã«æŽ»åãã補è¬ã¡ãŒã«ãŒãšãå»çè¡çºã«é¢ãããã¥ã«ã³ãã«ã¯èŠç¯ããåœå®¶ãã°ããŒãã« NGO ã®äž¡æ¹ã«ãã£ãŠå»çå«çã®äžè¬èŠç¯ã«æ¡åŒµããããã¹ãŠã®å»åž«ãšè£œè¬äŒç€Ÿãææãããããšã«ãã£ãŠæºããããããšãæåºããããã¥ã«ã³ãã«ã¯ã»ã³ãŒãã¯ããã®å
šäœãã©ã®åœã§ãæ£åŒã«æ³åŸãšããŠæ¡çšãããããã§ã¯ãªãããã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ããšããåºæ¬èŠä»¶ã¯äžççã«åãå
¥ããããŠãããåœéæ³ã§ã¯åœé£åžæ°çåã³æ¿æ²»çæš©å©ã«é¢ããåœéèŠçŽïŒ1966ïŒã®ç¬¬7æ¡ã§æ確ã«èŠå®ãããŠãããã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãã¯ããã¥ã«ã³ãã«ã¯ç¶±é ã«ç¹ã«äŸæ ããŠãããäžçä¿å¥æ©é¢ãšå»åŠåœéçµç¹åè°äŒãå
¬åžããææ°ã®ã¬ã€ãã©ã€ã³ã§ããã人éã察象ãšããçç©å»åŠç 究ã®ããã®åœéå«çã¬ã€ãã©ã€ã³ãïŒ1993幎ïŒã®åºç€ã«ããªã£ãŠããã
40 ii.Opinio Juris sive necessitatis requirement - ç§ãã¡ã¯ããã¥ã«ã³ãã«ã¯ã»ã³ãŒãã®å«çåºæºããå»åŠå«çã®äžè¬èŠçŽãéããŠäžççã«èªç¥ãå容ãæ¡çšãå®è·µãããŠããããšã¯ãå»åž«ãšè£œè¬ã¡ãŒã«ãŒããã®ååãéµå®ãã矩åã«çžåœããããšãæåºããããã¥ã«ã³ãã«ã¯ã»ã³ãŒãã®10ååã®ããããã«éåããããšãå€æããå»åž«ãç 究è
ã¯åäºè²¬ä»»ãåãããããšã«ãªãã®ã§ããŠã¹ã»ã³ãŒã²ã³ã¹æ
£ç¿èŠç¯ã®ååã®äžã§åœéæ³ã®æºæµãšããŠãã¥ã«ã³ãã«ã¯ã»ã³ãŒããé©æ Œãšããopen jurisèŠä»¶ãæºãããããšæåºããã
41 ä»å¹Žãã€ã®ãªã¹ã«ãããŠãã€ã®ãªã¹æ¿åºããã³ãã®é£åãé«å®ããäžã€ã®åŽé¢ã ãã§ãªããå€ãã®åŽé¢ã§ãã¥ã«ã³ãã«ã¯ã»ã³ãŒãã«éåããããšãã詳ãã玹ä»ããã®ãç§ãã¡ã®æå³ã§ããã
42 a) å»åŠå®éšã«åå ããããã®ã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ã
ãã¥ã«ã³ãã«ã¯ç¶±é ã®ç¬¬äžã®ååã¯ãæ²»çãåããå®éšã«åå ããæ¬äººã®ææãšã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãã§ãããæ¬äººãæ³å®ããŠããã®ã¯
åãåœããè©æ¬ºãè
è¿«ãå§èªããã®ä»ããããçš®é¡ã®ææã匷å¶ã«ããä»å
¥ãªãã«ãéžæã®èªç±ãçºåãããã
43 è±åœã§åççã®é·ãéŠçžãã¯ã¯ãã³ãçºè¡šããè±åœäœæ°ãžã®æ¥çš®ãéå§ãããšãã被æ¥çš®è
ã¯ãå®éã«ã¯å»çå®éšã«åå ããããšã«ãªãããšããã¥ã«ã³ãã«ã¯ç¶±é ã«åºã¥ãåæãå¿
èŠã§ããããšãç¥ããããŠããªããããã¯ãäºå®äžããã¥ã«ã³ãã«ã¯ç¶±é ã«éåããé倧ãã€é²éªšãªã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ããªãã«è¡ããã人éã«å¯ŸããéºäŒåå»åŠå®éšã§ããã
44 b) 代æ¿çæ³
- å»çè¡çºã«å¯Ÿããã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãã«ã€ããŠã¯ããã¥ã«ã³ãã«ã¯ã»ã³ãŒãã®ååã«åºã¥ããæ£è
ãåžæããæ²»çã«é¢ããŠç¥çãªå人ç決å®ãè¡ããããã«ãå»çéçšïŒããã³ããã«å«ãŸãããã¹ãŠã®ãã®ïŒããã³ãã¹ãŠã®æ²»çã«ååšããå©ç¹ãšæ¬ ç¹ãå©çãšå±éºæ§ã詳述ããŠãããã€ãã®æ²»çéžæè¢ãæ£è
ã«ææ¡ãã矩åãååšããŸãããã®éžæã¯ãåè¿°ã®ãšãããå人ã®èªç±æå¿ã«åºã¥ããã®ã§ãªããã°ãªããªãã
45 äžèšã®ãã¹ãŠã«ãããããããè±åœæ¿åºãšä¿å¥çã¯ãCovid 19 ã®æ²»çæ³ãšããŠçŸåšååšãã代æ¿æ³ãè±åœåœæ°ã«æ瀺ããããšãæ ãç¶ããŠããã代æ¿çæ³ã¯ãçŸåšãCovid 19ã®æ²»çã«ãããŠæ¥µããŠå®å
šã§ããã極ããŠæå¹ã§ããããšã蚌æãããŠãããäžèšã®ä»£æ¿çæ³ã§ã¯æ倧100ïŒ
ã®æåçãèªã£ãŠããŸããè±åœæ¿åºã¯ãã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ãã®ããã»ã¹ã«ãããããŸã«éåããŠãåœæ°ã«å§åããããæäœããäºé²æ¥çš®ã«é¢ããæ
å ±ãæå³çã«é ããææãšåŒ·å¶ã®é°å²æ°ãäœããªãããå§èªãç¶ããŠããã®ã§ãã
c) å®éšã¯ãèŠçã身äœçæå·ãé²ãããã«è¡ãããã
46 m-RNAãã¯ã¯ãã³ãæ²»çã«ãããå€ãã®äººãæ»äº¡ãããŸããã¯ã¯ãã³ãæäžåŸã«å·å®³ãé床ã®é害ïŒèº«äœé害ã麻çºãå«ãïŒãçºçããããšãç¥ãããŠãããã«ãããããããæ¿åºã¯ãã®ä»¶ã«é¢ãã調æ»ãéå§ããããæ瀺ããªãã£ãããŸãããã®ã¯ã¯ãã³æ¥çš®ã®å®éšçæ§æ Œã«éã¿ãæ»äº¡è
æ°ãå·å®³è
æ°ã麻çºè
æ°ãªã©ã®å®å
šãªå ±åããªãããšãçåã§ããã
ãã®ãããªå»çããã»ã¹ã§ã¯ãå®éšã«åå ããäžè¬åžæ°ã®ããã«ãè² å·è
ãåºãããšãäºæ³ãããã
d) å®éšã¯ãæ»äº¡ãŸãã¯è² å·ãããšæ³å®ãããçç±ãããå Žåã¯ãè¡ã£ãŠã¯ãªããªãã
å®å·å®³ãçºçããã
47 - ãã®ååã®éåã«ã€ããŠã¯ãäžèšã®ããã«ãæ»äº¡äŸã®ããŒã¿ã¯
ç§ãã¡åžæ°ã¯ãåœå¶ã¡ãã£ã¢ããã§ã¯ãªããå£ã³ãããœãŒã·ã£ã«ãããã¯ãŒã¯ïŒå人ãé£äººã芪é¡ïŒããããæ
å ±ãåŸãããŸããã
e) å®éšã®è²¬ä»»è
ã¯ãå®éšåå è
ã«å·å®³ãé害ãæ»äº¡ããããããšä¿¡ããã«è¶³ãçç±ãããå Žåãã©ã®æ®µéã§ãå®éšãäžæ¢ããçšæãããŠããªããã°ãªããªãã
48 - m-RNAæ²»çã«ãã£ãŠå€ãã®äººãæ»äº¡ããè² å·ããé害ãè² ã£ãããšããã§ã«èšŒæãããŠãããããããã€ã®ãªã¹æ¿åºã¯ãã®å±éºãªå®éšãåœæ°ã«åŒ·å¶ãç¶ããŠããã®ã§ããã
C.ããŒãæ³ç
49 ããã«ãä»å¹Žãè±åœã«ãããŠãè±åœæ¿åºããã³ãã®é£åãé«å®ããåœéåäºè£å€æã®ããŒãèŠçšã«äžé¢ã ãã§ãªãå€é¢çã«éåããããšã玹ä»ãã詳ãã説æããããšãæã
ã®æå³ã§ããã
第6æ¡ ãžã§ããµã€ã
50 ããŒãèŠçšç¬¬6æ¡ã«åŸãã-ããžã§ããµã€ãããšã¯ãåœå®¶çãæ°æçã人皮çãŸãã¯å®æçéå£ã®å
šéšãŸãã¯äžéšãç Žå£ããæå³ãæã£ãŠè¡ããã次ã®ããããã®è¡çºãæå³ããã
(a) ãããã®éå£ã®æ§æå¡ã殺害ããããšã
51 - ãã®å Žåã®éå£ãšã¯ãååãšããŠãé«éœ¢è
ãæ
¢æ§çŸæ£è
ãé害è
ããå§ãŸããã€ã®ãªã¹ïŒããã³äžçïŒã®å
šäººå£ãã§ããã
(b) éå£ã®æ§æå¡ã«é倧ãªèº«äœçãŸãã¯ç²Ÿç¥çå±å®³ãå ããããšã
52 - ãŠã€ã«ã¹ã«åããŠææããŠãã8ã«æåŸã«é·æçãªåœ±é¿ã蚌æãããŠããããšïŒä»é²20
53 - ãã¯ã¯ãã³ãã«ããçæçãªè¢«å®³ãšæ»äº¡ã倧éã«çºçã2021幎11æ24æ¥çŸåšãè±åœã§ã¯ããã¡ã€ã¶ãŒã®ãã¯ã¯ãã³ãã§136,582件ãã¢ã¹ãã©ãŒãã«ã®ãã¯ã¯ãã³ãã§238,086件ããã¢ãããã§19,101件ãéæãç¹å®ãããŠããªããšããã§1,280件ã®ã€ãšããŒã«ãŒããå ±åãããŠãããã€ãŸããè±åœã ãã§åèš395,049件ã®å¯äœçšãå ±åãããã€ãšããŒã«ãŒãå ±åå¶åºŠã«å ±åãããã«è¶³ãé節ãªãã®ã§ããïŒæ·»ä»ææž20ïŒã
54 - ã¯ã¯ãã³æ¥çš®è
ã«äžèšã®ãããªé·æç圱é¿ãæåŸ
ããã
55 - çµ±èšç蚌æ ã¯ããã¯ã¯ãã³æ¥çš®ãåŸã®æ»äº¡ã®å€§å¹
ãªå¢å ã瀺åããŠããïŒä»é²21ïŒã
56 - 24æé365æ¥ã®å¿çæŠãããã¬ã³ããåœéœæ§ã®PCRæ€æ»ãå»çã®æ¬ åŠã倧éäºé²æ¥çš®ã«ããèšãç¥ããªã粟ç¥ç被害ã
57 - ã¢ã«ã³ãŒã«äŸåçè
ã®åçºãæé£é害ã®åçºãç£çŠã«ããå°å瀟äŒã§ã®ç®¡çäžèœã®å¢å ã
58 - ãã£ã€ã«ãã©ã€ã³ã«é»è©±ãã匱ãç«å Žã®åã©ãã®æ°ã¯ãããã¯ããŠã³ãã37ïŒ
å¢å ããïŒæ·»ä»è³æ22ïŒã
(c) éå£ã«æ
æã«ç掻æ¡ä»¶ãäžãããããããããããã«èšç®ããããšã
å
šéšãŸãã¯äžéšãç©ççã«ç Žå£ããããšã
59 - æŒãä»ããããããã¯ããŠã³ã«ããå¯ãšäºæ¥ã®ç Žå£ïŒAppendix 23)
60 - ãŠã€ã«ã¹ã«ææãã人ãm-RNAãã¯ã¯ãã³ããæ¥çš®ãã人ããã¹ã¯ççšçŸ©åã匷å¶æ€æ»äœå¶ã§å
ç«ç³»ã«ãã¡ãŒãžãäžããã
61 ã³ãããã¯ã¯ãã³ããæ¥çš®ãã人ã¯ããã倧ããªãªã¹ã¯ãè² ã£ãŠããããšãçµ±èšçã«èšŒæãããŠããã
ãŸãã被æ¥çš®è
ã®å®¶æãŸã§ããç
æ°ã«ãªããå Žåã«ãã£ãŠã¯æ»äº¡ããŠãããããã¯ãæªæ¥ãã©ããªããã瀺ã極ããŠææ
®ãã¹ãã·ã°ãã«ã§ããã(ä»é²24)
(d) éå£å
ã§ã®åºç£ãé²æ¢ããããšãç®çãšããæªçœ®ã®å®æœã
62 - Covid m-RNA 'ã¯ã¯ãã³æ¥çš®åŸã®èªç¶æµç£ã®å¢å ã蚌æããããNew England Medical Journalã«æ²èŒãããæè¿ã®ç 究ã§ã¯ã第3æ以åã®ã³ãããã¯ã¯ãã³ãæååŸã10人ã«8人ã®å¥³æ§ãæµç£ããããšã瀺ãããŠããŸãïŒæ·»ä»è³æ25ïŒã
63 - m-RNAããã®DNAé
åã®æå³çãªå€æŽã«ãããã³ãã-ãã¯ã¯ãã³æ¥çš®ãåŸã®çæ®èœåã®äœäžãäºæ³ãããïŒä»é²26ïŒã
第7æ¡ äººéã«å¯Ÿãã眪
64 ããŒãèŠçšç¬¬7æ¡-人éã«å¯Ÿãã眪ã«åŸããããããåžæ°éå£ã«åããããåºç¯ãªãŸãã¯çµç¹çãªæ»æã®äžéšãšããŠãæ»æãç¥ããªããè¡ãããå Žåã®ä»¥äžã®è¡çºã®ãããããæå³ããŸãã
(a) 殺人
65 - 以äžã«ç€ºãåœå®¶çµ±èšå±ïŒONSïŒã®çµ±èšïŒä»é²27ãåç
§ïŒã§ã¯ã2021幎1æ2æ¥ãã202l幎7æ2æ¥ã®éã«ãã³ãããã¯ã¯ãã³ååæäžãã21æ¥ä»¥å
ã«18,653人ãæ»äº¡ãããã®ãã¡4,388人ïŒ30%ïŒãã³ããã19ãŠã£ã«ã¹ã«é¢äžããŠãããšèšé²ãããŠããŸããååæäžãã21æ¥ä»¥äžçµéããæ»äº¡è
æ°73,822人-ãã¡7,289人ïŒ11ïŒ
ïŒãã³ããã-19ãŠã€ã«ã¹ã«é¢äžããŠããã2åç®ã®æäžåŸ21æ¥ä»¥å
ã®æ»äº¡è
11,652人-182人ïŒ1.5ïŒ
ïŒãã³ããã-19ãŠã€ã«ã¹ã«é¢äžããŠããã2åç®ã®æäžåŸ21æ¥ä»¥äžã®æ»äº¡è
57,721人-458人ïŒ0.8ïŒ
ïŒã§ãã
66
以äžã®è¡šïŒä»é²28ïŒã«ç€ºãONSã®ãããªãããŒã¿ã¯ã2021幎1æã®æ»äº¡ç»é²æ°ã2020幎1æã«æ¯ã¹ãŠ23ïŒ
å¢å ããŠããããšã瀺ããŠãããåæ§ã«ã2020幎2æãšæ¯èŒããŠ2021幎2æã§ã¯ãå
šäœã®æ»äº¡æ°ã26ïŒ
å¢å ããŠãããæã
ã¯ãã³ããã19ãã¯ã¯ãã³ãã2020幎12æã«è±åœã§å±éãããçŽç²ã«ãã¯ã¯ãã³ããèªç±ã«ãæ¿æ²»çå§åã匷å¶ãªãã«æåããææããã人ã¯èª°ã§ããå±éã®æåã®æ°é±é以å
ã«ããããã€ããã ã£ãããšãç¥ã£ãŠããããã®å®éšçã¯ã¯ãã³ã®å°å
¥åŸ8é±é以å
ã«æ»äº¡ãé©ç°çã«å¢å ããããšã¯ãæ§ããã«èšã£ãŠãé©ãã¹ãããšã§ãæ³å»·ã«ããå®å
šãªèª¿æ»ãåããã«å€ãããã®ã ã
67 è±åœã§ã¯ãã³ãŽã£ã 19 ãéœæ§ãšãªã£ãå Žåã絶察ã«åŒåžãã§ããªããªããŸã§èªå®
ã«éé¢ããããã®æç¹ã§ç
é¢ ã«è¡ã人工åŒåžåšãä»ããããã»ãšãã©ã®å Žåæ»ã«è³ããšããæé ã«ãªã£ãŠããã人工åŒåžåšãè£
çããã³ãã19æ£è
1023人ã®ç 究ïŒä»é²29ïŒã§ã¯ã42ïŒ
ãæ»äº¡ãã57ïŒ
ãçåããŠããããšãããã£ããæã
ã¯ãã³ãŽã£ãã-19ã«å¯Ÿããå®å
šã§å¹æçãªä»£æ¿æ²»çã®æå§ã¯æ®ºäººã«çãããè£å€æã«ããå®å
šãªèª¿æ»ãå¿
èŠã§ãããšæå±ããã
68 以äžã®ONSããåãããããŒã¿ã¯ã2020幎4æäžã«ã±ã¢ããŒã ã§çºçããæ»äº¡ã¯26,541件ã§ã5幎平åã§17,850件å¢å ããããšã瀺ããŠããã(æ·»ä»è³æ 52 )
69 ãªãããŒã«ã»ã±ã¢ã»ãã¹ãŠã§ã€ã¯é人éçãšå€æãã2014幎ã«æŸæ£ããããã2020幎åé ã®ãã³ãããã¯éå§æã«åŸ©æŽ»ããè±åœäžã®ã±ã¢ããŠã¹ã§å®æœãããŠããããšã瀺ã蚌æ ã§ãããäžé¢ã®ææžã§ããããã»ãã³ã³ãã¯ãšä¿å®å
ã®è°å¡ã«ãŒã¯ã»ãšãŽã¡ã³ã¹å士ã¯ãã³ããæ£è
ã«ãè¯ãæ»ããäžããããã®è¬ç©äœ¿çšïŒå®æ¥œæ»ïŒã«ã€ããŠè°è«ããŠããã
(æ·»ä»è³æ 30)
70 202幎3æããã³ã³ãã¯ã¯ãã©ã³ã¹ã®ãµãã©ã€ã€ãŒã«ãããŸã©ã ãšããé®éå€ã2幎åçºæ³šããïŒæ·»ä»è³æ31ïŒããã®æ³šæããªããããšãããããŸã©ã ã¯ã³ãŽã£ãã19æ£è
ã®æ²»çã®ããã§ãããšäž»åŒµããã-ãããŸã©ã ã¯åŒåžåšç³»ãæå¶ãã-ã³ãŽã£ãã19ã¯åŒåžåšç³»ã®ç
æ°ã§ãããæã
ã¯ãè±åœæ¿åºããªãåŒåžæå¶ãšåŒåžåæ¢ãåŒãèµ·ããç
æ°ã®æ²»çã®ããã«ãåŒåžæå¶ãšåŒåžåæ¢ã«é¢é£ããè¬ã§ãããããŸã©ã ã2幎å賌å
¥ããã®ãã«ã€ããŠãè£å€æãååãªèª¿æ»ãè¡ãããšãèŠæ±ããã
71 ãã®ææžïŒä»é² 32ïŒã§ã¯ãé«éœ¢è
ãäœèª¿äžè¯è
ãžã®ãããŸã©ã ã®æäžé㯠0.5mg-1mg 以äžã§ããããšã å¯äœçšãšããŠå¿èºæå¶ããããåŒåžåšçŸæ£ã®ãã人ã«ã¯æ
éã«äœ¿çšããããšã確èªããè¡šãæ²èŒãããŠããã
72 NHSãäœæããææžïŒä»é²33ïŒã§ã¯ããããã¶ã ã¯Covid-19ã«ããçµæ«æã±ã¢ã®å¿«é©ãã®ããã«äœ¿çšãããææãäžå®ãè奮ãåãããã¹ãã§ãããšè¿°ã¹ãŠããããã®ææžã§ã¯ããããŸã©ã ã¯æ£è
ã人工åŒåžãå¿
èŠãšããåã«é®éã®ããã«äœ¿çšãããã¹ãã§ãããšè¿°ã¹ãŠããããŸããåææžã§ã¯ããããŸã©ã ã¯ç¹ã«ç
æ°ãé«éœ¢ã®å ŽåãåŒåžã·ã¹ãã ãæãªãå¯èœæ§ãããããšã確èªããæäžéã¯æå°éã«ãšã©ããã¡ãŒã«ãŒã®ã¬ã€ãã©ã€ã³ã®ç¯å²å
ã§è¡ãã¹ãã§ãããšæèšããŠããŸãã
73 é«éœ¢è
ãè匱ãªæ£è
ã«å¯Ÿããæšå¥šçšéã 0.25mg ã§ããã«ãããããããã³ããã 19 ã«ãã£ãŠäžå®ã«é¥ã£ããšãããæ£è
ã 2.5mg ã®ãããŸã©ã ã®éå§çšéã§æ²»çããæ¹éãäœæããããšã¯ãäžæ³ãªå®æ¥œæ»ããã³æ®ºäººã«çžåœããè£å€æã«ããå®å
šãªèª¿æ»ãåãã䟡å€ããããšæã
ã¯æ èšããã
74 ããã«ãå€æ°ã®ã¯ã¯ãã³æ¥çš®è
ãéçåããè¿ãå°æ¥ãå
ç«ã·ã¹ãã äžå
šãæäœäŸåæ§å¢åŒ·ã§æ»äº¡ããå±éºæ§ãããïŒæ·»ä»è³æ34ïŒã
(b) é§é€
75 è±åœäººå£ã®å€§éšåïŒããã³äžç人å£ïŒããæè¿ã®mRNAãã¯ã¯ãã³ãã«ãã£ãŠéç
ãŸãã¯æ»äº¡ã®å±éºã«ãããããŠãããšèããååãªçç±ãããã2012幎ãã2013幎ã«ãããŠè¡ãããmRNAã¯ã¯ãã³ã®åç©å®éšïŒä»é²35ãš36ïŒã§ã¯ãã»ãšãã©ã®åç©ãæ²»çãåããŠãã2é±é以å
ã«æ»äº¡ããŠãããããã¯äººéã®1.5幎åã«çžåœãããã¯ã¯ãã³æ¥çš®è
ã¯ããŠã€ã«ã¹ãšå
šãåãã人工ã¹ãã€ã¯ã¿ã³ãã¯è³ªãã«ãããããŠããã®ã§ãããŠã€ã«ã¹ãã¯ã¯ãã³ã人éã®DNAãå€åãããããšã蚌æãããŠããïŒæ·»ä»è³æ37ïŒãã³ãããã¯ã¯ãã³æ¥çš®ããåããå
ç«ç³»ãå
ã®ç¶æ
ã«æ»ãããšã¯ãŸããªãããã®äŸé Œã®å
±åç³è«è
ã§ãããã€ã¯ã»ã€ã§ãã³å士ãå«ãäœäººãã®é«äœã®å
ç«åŠè
ãšã¯ã¯ãã³èšèšè
ã¯ãææªã®ã·ããªãªã§ã¯ããããã®m-RNAæ²»çãåãã人é¡ã®ã»ãšãã©ãæ»
亡ãããšèŠåããŠããã
(e) æçãŸãã¯ãã®ä»ã®èº«äœçèªç±ã®å³ããå¥å¥ªã®éå
åœéæ³ã®åºæ¬çãªã«ãŒã«
76 - åœå
å€ãžã®æž¡èªã®èªç±ãçŠæ¢ããããšã
77 - 匷å¶çãªç£çŠãšçµæžæŠäº-ç¹ã«äžå°äŒæ¥ã®çµå¶è
ã«å¯ŸããŠ-çåã®ããã«åœå®¶ã«äŸåããããšã匷ããã
78 - æµ·å€æ
è¡ããåž°åœããPCRæ€æ»ãã©ããããããŒãã¹ãã§å¥åžžè
ãšåœéœæ§ãåºãå Žåãããã«ã§åŒ·å¶çã«éé¢ãããã
79 - NHSã®è¿œè·¡ã¢ããªã®èŠæ±ã§åŒ·å¶çã«ãèªå·±éé¢ããããã
80 - æ
è¡ãå人蚪åãããŒãã£ãŒã®æé
ãæåã»ã¹ããŒã掻åãžã®åå ãå®æçéäŒãªã©ã§ã身äœçèªç±ãèãã奪ãããã
(f)æ·å
81 - å¿ççãªææãšæŠäºïŒç²Ÿç¥çæ·åïŒã¯ãæ¿åºãåœå®¶ã¡ãã£ã¢ãäž»æµã¡ãã£ã¢ããããŠFacebookãTwitterãYouTubeãGoogleãªã©ã®ãœãŒã·ã£ã«ã¡ãã£ã¢ãã©ãããã©ãŒã ã«ãã£ãŠç®¡çãããŠããŸãã
(g) 匷姊ãæ§å¥Žé·ã匷å¶å£²æ¥ã匷å¶åŠåš ã匷å¶åŽåã
äžåŠæè¡ããŸãã¯ããã«å¹æµããé倧æ§ãæã€ä»ã®ãããã圢æ
ã®æ§çæŽåã
82 - å€ãã®å»åž«ãç§åŠè
ã瀺åãããã¯ã¯ãã³ãã®å¹æã®ã²ãšã€ã¯ãã³ãããã¯ã¯ãã³ããåããåŠå©Šã«ããå€ãã®èªç¶æµç£ïŒæµç£ã䌎ãã匷å¶çäžåŠæè¡ãã§ãïŒä»é²38ã39ïŒã
(h) æ¬é
ã«ããè¡çºåã¯è£å€æã®ç®¡èœå
ã®ç¯çœªã«é¢é£ããŠãæ¿æ²»çã人皮çãåœæ°çãæ°æçãæåçãå®æçã第3é
ã«å®çŸ©ããæ§å¥åã¯åœéæ³ã®äžã§èš±ãããªããã®ãšããŠæ®éçã«èªèãããŠãããã®ä»ã®äºç±ã«ãããèå¥å¯èœãªéå£åã¯éå£ã«å¯ŸããŠè¡ã迫害ã
83 - ã¯ã¯ãã³æ¥çš®ãåããŠããªãè
ã«å¯Ÿãã迫害ã倱è·ãå
¬çè¡äºãžã®åå æåŠ
84 - ãã¹ãŠã®å®æå£äœã«å¯Ÿãã迫害ã¯ã瀌æã®å Žæãžã®åºåžã劚ããããŠããã
(j)ã¢ãã«ããã€ã
85 - æ°ãããã¯ã¯ãã³ãã¹ããŒããã®æ¬åœã®å¹æã¯ã人ã
ã«äºé²æ¥çš®ãåããããå§åããããäºé²æ¥çš®ãåããªã人ã
ããæ
è¡ãä»äºã瀟äŒåå ãéåžžéãè¡ãæš©å©ã奪ããšããå©çã®ããã«ãæ°ãã圢ã®å»çã¢ãã«ããã€ããå°å
¥ããããšã§ããã
(k)ãã®ä»é¡äŒŒã®é人éçè¡çºã§ãæ
æã«å€§ããªèŠçãäžããåã¯
身äœãŸãã¯ç²Ÿç¥çãããã¯èäœçãªå¥åº·ã«é倧ãªæ害ãäžããããšã
86 - 瀟äŒçè·é¢ã®åãæ¹ããã¹ã¯ã®çŸ©åä»ããææãç
œãããšãã¯ã¯ãã³æ¥çš®ã®å§åããããŠãã¯ã¯ãã³ããã®ãã®ãã身äœãå¿ãéã«æ·±å»ãªå·ãäžããçç±ãšãªãã
第8æ¡ æŠäºç¯çœª
87 æŠäºç¯çœªã®æèçèŠçŽ - çç©å
µåšSARS-Cov-2ãšè¿œå çç©å
µåšm-RNAéºäŒåæ²»çãã¯ã¯ãã³ãã®çºè¡šãéããŠãè±åœïŒããã³äžçïŒã®äººã
ã«å¯ŸããŠç§å¯æŠäºãè¡ãããããšããæã
ã¯æåºãããç§ãã¡ã¯ãè±åœïŒããã³äžçïŒã®äººã
ããåè¿°ã®çç©å
µåšãæŸåºããè
ãã¡ããããããŠç§ãã¡ããã®èŠæ±ãçªãã€ããè±åœæ¿åºå
ã®äººç©ãåœéçæå°è
ãã¡ãããåãè°é¡ã§å¥ä»ããããšããçµç¹çãªæ»æãåããŠãããšäž»åŒµããããããã£ãŠãæã
ã¯ãæŠäºç¯çœªã®æèçèŠçŽ ãæºããããŠãããç³ãç«ãŠãããç¯çœªã¯åœéçããã³éåœéçãªæŠåçŽäºã®æèã§è¡ãããããšãæåºããã
88 ã¡ã³ã¹ãªã¢èŠçŽ ç§ãã¡ã¯ããã«ãç§ãã¡ããã®èŠæ
ãç³ãç«ãŠãè±åœæ¿åºã®ã¡ã³ããŒããã³äžçã®åœéçæå°è
ãã¡ã¯ãSARS-Cov-2ããã³m-RNAãã¯ã¯ãã³ããšããŠç¥ãããçç©å
µåšãéããŠã人å£æžå°ãç®çãšãããã®ã°ããŒãã«ã¢ãžã§ã³ãã代衚ããŠæ
æã«æŽ»åããŠããããšãæåºããããããã£ãŠãç§ãã¡ã¯ããã®èšŽç¶ãæåºããè±åœæ¿åºã®ã¡ã³ããŒããã³äžçã®æå°è
ãã¡ã¯ããããã®ç³ãç«ãŠãããç¯çœªã«é¢ããŠç¥èãšæå³ã®äž¡æ¹ãæããŠããããšãæåºããã
89 åœè£å€æã¯ãç¹ã«ãèšç»ãæ¿çã®äžç°ãšããŠããããã¯ãã®ãããªç¯çœªã®å€§èŠæš¡ãªå®è¡ã®äžéšãšããŠè¡ãããæŠäºç¯çœªã« ã€ããŠã®ç®¡èœæš©ãæãããã®ãšããã
90 ããŒãèŠçšç¬¬ 8 æ¡ã«ããã°ããæŠäºç¯çœªããšã¯ã以äžã®ãã®ãæå³ããã
(a) 1949 幎 8 æ 12 æ¥ã®ãžã¥ããŒãæ¡çŽã®é倧ãªéåãããªãã¡ãé¢é£ãããžã¥ããŒã æ¡çŽã®èŠå®ã«åºã¥ããŠä¿è·ããã人åã¯è²¡ç£ã«å¯Ÿãã次ã®ããããã®è¡çºã
(i) æ
æã®æ®ºå®³
91 - ç§ãã¡ã¯ããã¯ã¯ãã³ãã«ããæ»äº¡çã®çµ±èšããŒã¿ãæäŸããŸãããããã¯ã¯ãã³ãã®æ¥çš®è
ãæ¯èŒçå€ãããã®æ°ã¯ããå€ãã®ãã¯ã¯ãã³ããæäžãããçµæå¢å ããŠããããããã®ãã¯ã¯ãã³ãã®ç¶ç¶ç䜿çšã¯æ
æã®æ®ºå®³ãæ§æãããšããè«çççµè«ã«éããŠããŸãã被害è
ã®å€ããé«éœ¢è
ã§ãã£ãŠããããè¥ãå¥åº·ãªäººã
ã®æ»äº¡ã被害ãæ¯èŒçé«ãå²åã§ååšããã
92 - ç§ãã¡ã¯ãã±ã¢ããŒã ã®æ£è
ã«æšå¥šéã®5åã®ãããŸã©ã ã䜿çšããããšããæ
æã®æ®ºäººã«çžåœãããšãã蚌æ ãæäŸããã
93 ãã¯ã¯ãã³ã«å«ãŸããæ°Žé
žåã°ã©ãã§ã³
(ii) æ·å
94 - Cov-SARS-2 Virusã¯äººå·¥çã«äœããããæ©èœç²åŸåãŠã€ã«ã¹ãã§ãããããã«åå°ãããèšå€§ãªææžã«ããã°ãããã¯å°ãªããšã10幎ãã15幎ã®éã«æŠæŒ¢ãŠã€ã«ã¹ç 究æã§ãçç©åŠçå®éšããšããŠäœããããã®ã§ããããã®ãŠã€ã«ã¹ã¯ãäºæ
ã«ãã£ãŠããããã¯æå³çã«ãæŸåºãããã
95 - ãã®ãããªçç©å
µåšã®éçºã¯ãããã ãã§ç¯çœªã§ããã
96-å§ä»»ã«ãããã¹ã¯ã®äœ¿çšããŸããçç©åŠçå®éšã«è©²åœããããã³ããŒã¯ã®ãã¹ã¯ã®ç 究ïŒä»é²40ïŒã§èšé²ãããŠããããã«ãããã¯å€§èŠæš¡ãªè¢«å®³ããããããŠããã
97 - è©Šéšç®¡ã䜿çšããäœçŸäžäººãã®äººéã®éŒ»ã«çãèªçºããååŠç©è³ªã䜿çšããããšããæããã«çç©åŠçå®éšãŸãã¯æŠäºã§ããã
98 - ããããã¯ã¯ãã³ã¯ç·æ¥çšãšããŠã®ã¿æ¿èªãããŠããããããã®éºäŒåæ²»çè¬ã®å€§é䜿çšã¯äººé¡å²äžæ倧ã®çç©åŠçå®éšã§ãããã¯ã¯ãã³æ¥çš®ã«ãã£ãŠãDNAã«äžå¯éçãªå€åãåŒãèµ·ãããŠããã
99 - ç§ãã¡ã®DNAã«å¯Ÿãããã®ãããªå®éšã¯ãã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ããªãã«ã人é¡ã«å¯ŸããŠè¡ãããææªã®ç¯çœªã§ããã
(3ïŒæ
æã«å€§ããªèŠçãäžãããããã¯èº«äœãå¥åº·ã«é倧ãªå·å®³ãäžããããšã
100 - ãã§ã€ã¹ãã¹ã¯ã®åŒ·å¶äœ¿çšã¯ãèäœçã«ã粟ç¥çã«ã倧ããªå®³ããããããã
101 - å»é¢ã®ééã¯ãå€ãã®éç
ãééã®ããã«æ°ã¶æé蚺æããããããã³/ãŸãã¯æ²»çãããã身äœãšå¥åº·ã«æããã«é倧ãªå·å®³ãåŒãèµ·ãããã
102 - ã¯ã¯ãã³ã¯ãçæçãªå¹æã®ã¿ã«åºã¥ããŠãæ»äº¡ãšå¥åº·ãžã®å€§ããªæå·ãåŒãèµ·ããããšã蚌æãããŠããŸãã
103 - ééã«ããå¿çæŠãšçµæžæŠã¯ãå»åŠçã»çç©åŠçæŠäºãšçžãŸã£ãŠãå¥åº·ã«ç倧ãªæ害ãäžããã
104 - Cov-Sars2ã«å¯Ÿããæå¹ãªè¬ïŒHCQãã€ãã«ã¡ã¯ãã³ïŒã®äœ¿çšæåŠã¯ã身äœãå¥åº·ã«é倧ãªæå·ãäžããè±åœã§äºé²å¯èœãªå€ãã®æ»äº¡ã®åå ãšãªã£ãŠããã
105 ã代æ¿çæ³ãžã®åŒŸå§
106 - æåçã®äœã人工åŒåžåšã®äœ¿çš
107 - ã±ã¢ããŒã ã§é«éœ¢è
ãå®æ¥œæ»ãããããã«ãããŸã©ã ã䜿çšãããŠããã
(iv) è»äºçã«æ£åœåãããªããåºç¯ãªè²¡ç£ã®ç Žå£ãšæšªé ã
å¿
èŠæ§ããããéåæ³ãã€æ¬²æã®ã¿ã§å®è¡ãããããšã
108 - äŒæ¥æŽ»åã®åºç¯ãªçµæžçç Žå£ãããã³å人ã®å¯ã
è±åœã®ããã¯ããŠã³ã«ããå人ããã³äŒæ¥æåŸã®å€§èŠæš¡ãªæšªé ãè¡ãããã
ããã¯ããŠã³ã®åœ±é¿ã«ããæ£åžžãªåå
¥ãåŸãããªã人ã
ã®ç§æ財ç£ãéè¡ãè²·ãåãã
109 - äžæµéçŽããè¶
å¯è£å±€ã®ã°ããŒããªã¹ããžã®å€§èŠæš¡ãªè²¡ç£ã®ç§»è»¢ãããããã®æ¿çã®äžççãªåž°çµãšãªãã ãããããã¯ãçŸä»£å²ã«ãããæ倧ã®åå°ãšæš©åã®å¥ªåãšè§£éã§ããã
(v) ãã®ãããªæ°é人ã«å¯ŸããããŸãã¯ãæ°é人ã«å¯Ÿããæå³çãªæ»æã®æ瀺ã
æµå¯Ÿè¡çºã«çŽæ¥åå ããŠããªãåã
ã®æ°é人ã
110 - ã€ã®ãªã¹ã®äººã
ïŒããã³å
šäººé¡ïŒã¯ãçŸåšããããã®åŒ·ç¡¬æªçœ®ãšå¿çã»çµæžæŠäºãšäžäœåããçç©æŠã«ãã£ãŠæ»æãåããŠããŸãã
(iv) ãã®ãããªæ»æããäºæ³ãããå
·äœçãã€çŽæ¥çãªå
šäœçè»äºçåªäœãšã®é¢ä¿ã§æããã«éå°ãªãä»éçãªæ°é人ã®çåœãè² å·ãæ°éç©ãžã®æ害ããŸãã¯èªç¶ç°å¢ãžã®åºç¯å²ãã€é·æçã§æ·±å»ãªæ害ãåŒãèµ·ããããšãç¥ããªãããæå³çã«æ»æãéå§ããããšã
111 - Cov-SARS-2ãŠã€ã«ã¹ã®äœæã¯ããã®æ»æãéå§ããããã®åææ¡ä»¶ã§ãã£ãã
112 - MERSãŠã€ã«ã¹ã«ã€ããŠã¯ã1990幎代ãšæåã®SARS1ãŠã€ã«ã¹ãŸã§ããã®ãŒãæç³»åãããããããŠãç±³è»ã®çç©åŠçç 究ïŒDARPAïŒãšãã©ã³ã¹ãã€ã®ãªã¹ããªãŒã¹ãã©ãªã¢ããããŠ15幎以äžã«ããã£ãŠè¡ãããäžåœã®ç 究ãšã®äž¡æ¹ãé¢é£ããŠããã
113 - ããããã°ããŒããªã¹ãã»ãšãªãŒããããŒãã¯ã©ããWEFïŒããã¹äŒè°ïŒãã°ããŒããªã¹ãæ¿æ²»å®¶ãå°çæ倧ã®è³æ¬å®¶ããããŠåœŒãã®èšç»ã§ããã¢ãžã§ã³ã2030ïŒåœé£ïŒãWHOãã倧ãªã»ããããšã®æ確ãªé¢é£æ§ãããã
114 - ãããã®äººã
ã¯ãäžççãªéçåã®å¿
èŠæ§ãã¯ã£ãããšèªã£ãŠããããšããããã«ã»ã²ã€ãã¯ãã¯ã¯ãã³æ¥çš®ããã®ããã®äžã€ã®æ¹æ³ã§ãããšè¿°ã¹ãŠããã
115-ãŠã€ã«ã¹ã®æ©èœç²åŸæäœã¯ãSARS 1ãšMERSãšä»ã®ãã¹ãŠã®ã³ãããŠã€ã«ã¹ãšæ¯èŒããŠã10-20åã«åºããããšãã§ãããŠã€ã«ã¹ã®ç¹æ§ãäžããŠããŸãããã®ã²ã€ã³ã»ãªãã»ãã¡ã³ã¯ã·ã§ã³ç 究ã®èåŸã«ããç§åŠè
ã¯ãå±éºãªåæãŠã€ã«ã¹ãäœãåºããŸããã
ãå°å
¥ããããã¥ã¡ã³ããäœæããŸãããHIVã®ããã«äŒç ãããããã®å±éºãª "Hiv GP120 "ã®æåãå«ãã§ããŸãã(ä»é²49)
116 - ãã®ãããžã§ã¯ãã¯ãæ°äž»äž»çŸ©äœå¶ããå
šäœäž»çŸ©çäžçãžãšå€è²ãããéžæã§éžã°ããã®ã§ã¯ãªãäžå€®ã®ãšãªãŒãã«ãã£ãŠæ¯é
ãããããšã«ãã£ãŠã人å£åæ
ãšæ¿æ²»ç¶æ³ã®äž¡æ¹ãæ ¹æ¬çã«å€ããããšããäžçã®é°è¬ã§ããããã«æãããŸãã
117-倧èŠæš¡ãªçåœã®ç Žå£ãçµæžæŠäºã®åœ±é¿ãå»çç·æ¥äºæ
ãšããããã®ã«é¢é£ãã倧èŠæš¡ãªå¿çæŠäºäœæŠãæåã®ç®çã¯ãæ£åžžã§ãªãç¶æ³ã«æ»ãããã®å¯äžã®ææžçãå¯äžã®å©çšã§ããæåã®ã¹ããããšããŠãéå£äºé²æ¥çš®ãåãå
¥ããããã«åœæ°ãæŽè³ããããšã
118 - 倧èŠæš¡ãªçµæžçã¡ã«ãããŠã³ã¯ã壮倧ãªèŠæš¡ã®éè厩å£ã«ã€ãªãããå°ãªããšããšãŒãããã§ã¯ãåœå®¶ãšé貚ãå®å
šã«åŽ©å£ãããã
119 - çµæžçãªç Žæ»
ãšå€§æšäºã«åºã¥ããçµæžåŽ©å£ãšæ¥ãã¹ã瀟äŒäžå®ã®çµæãšããŠãæå³ä»€ãå°å
¥ãããå¯èœæ§ãé«ããåœé²æ³2020ã®äžã§ããã³ãããŠã€ã«ã¹ã®è延ãæããNHSãå®ããåœãæãããã«å·è¡åã匷åãããããã®æ°ããæš©éãèŠå¯ã«äžããããã
I20 - éèå±æ©ã«ãããéè¡ãšäžå€®éè¡ã®äž¡æ¹ã厩å£ããç§æ財ç£ã倧èŠæš¡ã«å€±ãããè¶
å¯è£å±€ã®ãšãªãŒãã®ã¿ãå©çãåŸãå¯èœæ§ãé«ãã
121 - æ°ããææžèŠåã財åå ±åã®é
ãã¯ããã®æŽèœãé
ãããã ãã§ããã
122 - ããããã¹ãŠãšãã®ä»ã®æªçœ®ã®äžã«ããã¯ã¯ãã³ããšåæ§ã«ãSARS2ãã®äžé·æçãªåœ±é¿ããŸããªãæããã«ãªãããããŸã§ã«ãªãèæžçãªèŠæš¡ã®å€§ç
ãšæ»ãåŒãèµ·ããããã
第8æ¡ Bis3ïŒäŸµç¥ã®çœª
123 æ¬èŠå®ã®ç®çäžãã䟵ç¥ã®çœªããšã¯ãèšç»ãæºåãããã³ããã®å®è¡ãæå³ããã
åœã®æ¿æ²»çåã¯è»äºçè¡åãå®è³ªçã«æ¯é
ãåã¯æ瀺ããå°äœã«ããè
ãããã®æ§è³ªãé倧æ§åã³èŠæš¡ã«ããåœéé£åæ²ç« ã®æçœãªéåãæ§æãã䟵ç¥è¡çºãéå§ãåã¯å®è¡ããããšã
124 ããã¯ãæ°å幎åããèšç»ãããŠããäžççãªç¯çœªã®é°è¬ã§ããã
125 ãèšç»ãã«ã¯ãäžéšã®äŸå€ãé€ããè¶
å¯è£å±€ãšã»ãšãã©ã®åœå®¶ã®æå°è
ãé¢ãã£ãŠããããšã¯ãä»ãæããã§ãããããã¹ã®WEFãããŒãã¯ã©ããªã©ã®åŒ·åãªã·ã³ã¯ã¿ã³ã¯ããWHOãGAVIãªã©ã®NGOãããã®åŒ·æš©çãªç¯çœªçé°è¬ã®äžå¿ã§ããããšãæããã§ãããBUILD BACK BETTER "ãšããå
¬åŒã¹ããŒã¬ã³ã®ããšãWHOäŒé·ãã¢ã¡ãªã«å€§çµ±é ãWEFäŒé·ãã€ã®ãªã¹éŠçžããã®ä»æ°ããããªãã»ã©ã®äžçã®æå°è
ããã®ã¹ããŒã¬ã³ã䜿ã£ãŠããã
126 ãã®æŽ»åã®ç®æšã¯ãåœé£ãæå±ããã¢ãžã§ã³ã2030ãéããŠãéžæã§éžã°ããã®ã§ã¯ãªããšãªãŒããæ¯é
ãããã¹ãŠã®æ°äž»äž»çŸ©åœå®¶ã段éçã«è§£äœããå°ç人é¡ã®èªç±ãšåºæ¬ç人暩ãç Žå£ããããšã«ãã£ãŠãæ°ããäžç秩åºãäœãåºãããšã§ãããããã«ãäžå°äŒæ¥ãç Žå£ããŠãã°ããŒãã«ã»ãšãªãŒããææãã倧äŒæ¥ã«åžå Žã·ã§ã¢ã移ãããšãç®çã§ãããã®ç®æšãéæãããã°ãã»ãšãã©ã®å Žåã人é¡ã¯å®å
šã«å¥Žé·åãããããšã«ãªãã
127 ããã¯ãå±éºãªçç©å
µåšããŠã€ã«ã¹ãã¯ã¯ãã³ããã¹ãçšãã³ããã¹ã¯ã®çŸ©åä»ãããã®ä»ãã¹ãŠã®æ段ã«ããè
åšã«ãã£ãŠè¡ãããŠããããããã¯ãã¹ãŠãåœå
æ³ã®éåã§ããã ãã§ãªããåœéé£åæ²ç« ãããŒãæ¡çŽããããŠç§ãã¡ã®åºæ¬ç人暩ã®æ ¹æ¬çãªéåã«ããããŸãã
128 ICC ã¯ãããããã¹ãŠãèæ
®ããäžã§ãã³ããã¯ã¯ãã³æ¥çš®ã®æ¡å€§ãéæ³ãªã¯ã¯ãã³æ¥çš®çšã ã¹ããŒãã®å°å
¥ããã®ä»ããã«è¿°ã¹ããçŸåšã€ã®ãªã¹ã®äººã
ã«å¯ŸããŠè¡ãããŠããããããçš®é¡ã®éæ³ãª æŠäºããè£å€æã®å·®ãæ¢ãåœä»€ã«ãã£ãŠé»æ¢ããããã«ãçŽã¡ã«è¡åãèµ·ããããšãæãæ¥åã§ãããšè ããŠããã
D.調æ»éå§ã®èŠæ±
129
管èœè£å€æ
è£å€æã®ç®¡èœæš©å
ã«ããç¯çœªã®çã
å
¥æå¯èœãªæ
å ±ã«åºã¥ãããã¥ã«ã³ãã«ã¯ç¶±é ã®éåããžã§ããµã€ãã人éã«å¯Ÿãã眪ããã³æŠäºç¯çœªãè¡ããããšä¿¡ããã«è¶³ãåççãªæ ¹æ ãããã
ç¯çœªã®å®è¡ãçãããå Žæãšæ¥æã
å°å
130 - äžèšã®ç¯çœªã¯ãã€ã®ãªã¹ïŒããã³äžçïŒã®é åã§è¡ããããšäž»åŒµãããŠããã
131 - è±åœã¯ç· çŽåœã§ãããããåœè£å€æã¯ã被å人ã®åœç±ã«ãããããã2000幎10æ4æ¥ä»¥éã«è±åœé å
ã§è¡ããããã¹ãŠã®è¢«çç¯çœªã«å¯ŸããŠè£å€æš©ãè¡äœ¿ããããšãã§ããã
132 - ç¹ã«ã第12æ¡(2)(a)ã¯ããåé¡ã®è¡çºãçºçããé åå
ã®åœããèŠçšã®ç· çŽåœã§ããå Žåãè£å€æã¯ç¬¬5æ¡ã«èšåããç¯çœªã«å¯Ÿãã管èœæš©ãè¡äœ¿ããããšãã§ãããšå®ããŠããããããã£ãŠããã®èŠè«ã§ç¹å®ãããç¯çœªå®¹çã¯ããŒãèŠçšã®ç· çŽåœã®é åã§è¡ããããã®ã§ããããã容çè
ãç· çŽåœã®åœæ°ã§ãããã©ããã«ããããããè£å€æã¯ãããã®ç¯çœªå®¹çã«å¯ŸããŠé åç管èœæš©ãæããïŒD. Akande, 'The Jurisdiction of the International Criminal Court over Nationals of Non-Parties:D. Akande, 'The Legal Basis and Limits', Jrnl Int'l Crim Justice 1 (2003), pp.618-650; G. Danilenko, 'ICC Statute and Third States', in A. Cassese, P. Gaeta & J. Jones eds., The Rome Statute Of The International Criminal Court:A Commentary, (2002), pp.1871-1897)ã
133 - 容çè
ã«åž°å±ããç¯çœªãåœè©²é åå
ã§çºçããéããè£å€æããã®è¡çºã«å¯Ÿãã管èœæš©ãè¡äœ¿ã§ããããã«ã¯ãç¯çœªãè¡ãããéã«å®¹çè
ãç· çŽåœã®é åã«ç©ççã«ååšããå¿
èŠã¯ãªãïŒPsecutor v..Saif Al-Islam Gaddafi and Abdullah Al-Senussi, Appeals Chamber, "Judgment on the appeal of Libya against the decision of 31 May 2013 entitled 'Decision on the admissibility of the case against Saif Al- Islam Gaddafi'", ICC-01/11-01/11-547-Red, 21 May 2014, para.62)
134
- è±åœã®é åã«ãããŠ......ãã......ã®éã«è¡ããããšãããç¯çœªã¯ãåœè£å€æã®æéç管èœæš©ã®ç¯å²å
ã«ããã
135 èš±å®¹æ§ çžè£æ§
a.æ³çãªåèè³æ
第 17 æ¡ïŒ1ïŒïŒaïŒåã³ïŒbïŒã¯ãè£å®æ§ã®ããã®äºéã®ãã¹ããå®ããŠããã
136 (i) 容èªæ§ç°è°ã«é¢ããæç¶ã®æç¹ã§ãåœå
ã¬ãã«ã§åãäºä»¶ã®ææ»åã¯èµ·èšŽãé²è¡äžã§ãããã©ããïŒç¬¬1ã®è¢ïŒãåã³ããããè¯å®çã«åçãããå Žåã«ã¯ã以äžã®éãã
137 (ii) åœããã®ãããªææ»ã蚎远ãè¡ãããšãæãŸãªããããããã¯çŽç²ã«è¡ããªããïŒç¬¬äºè¢ïŒïŒProsecutor v. Germain Katanga and Mathieu Ngudjolo Chui, Appeals Chamber, "Judgment on the Appeal of Mr. Germain Katanga against the Oral Decision of 12th June 2009 on Admissibility of Case", ICC-01/04- 01/07-1497, 25 September 2009 ("Katanga Admissibility Appeals Judgment"), paras.1 ããã³ 75-79ïŒã
138 第 1 é
ã«åºã¥ãåœå®¶ã®äžäœçºã¯ã第 17 æ¡(1)(d)ã«åºã¥ãé倧æ§ã®è©äŸ¡ãæ¡ä»¶ãšããŠãè£å€æã«ãã ãäºä»¶ã®èš±å®¹æ§ãäžããïŒã«ã¿ã³ã¬èš±å®¹æ§æ§èšŽå¯©å€æ±ºããã© 78ïŒãæ€å¯ã¯ãæ€å¯ã«ããææ»ã®çŠç¹ãšãªãå¯èœæ§ãé«ãäºä»¶ã«é¢é£ããŠãçžè£æ§ã«é¢ããå€æïŒè€æ°å¯ïŒãè¡ãã
139 æ¡æã®èš±å®¹æ§èŠå®ã¯ãICC ãšãååœã®åäºåžæ³ãã®éã®è£å®çãªé¢ä¿ã«åºã¥ããŠããããã®ãããååãšããŠã17 æ¡(1)(a)ïœ(c)ã®é©çšãåŒãèµ·ããããšãã§ããã®ã¯ãåœå®¶ã®åœå
åäºææ»åã³ïŒåã¯èšŽè¿œã®ã¿ã§ããã
140 éå
éåã®è©äŸ¡ã¯ããç¶æ³ãã®èª¿æ»ããçããå¯èœæ§ã®ããäºäŸãèæ¯ãšããŠå®æœãããïŒã±ãã¢ç¬¬15æ¡æ±ºå®æžãparas.50, 58, 188; Co te d'Ivoire Article 15 Decision, para.202)ã
141
éåè©äŸ¡ã«ã¯ãè©äŸ¡ã«é¢é£ãã人ç©ãŸãã¯éå£ããç¯ããããšãããç¯çœªã«å¯ŸããŠæ倧ã®è²¬ä»»ãè² ãå¯èœæ§ã®ãã人ç©ãæããŠãããã©ããã®äžè¬çãªæ€èšãå«ãŸããããŸããè©äŸ¡ã¯éçåã³è³ªç芳ç¹ããè¡ãããªããã°ãªãããç³ãç«ãŠãããç¯çœªã®æ§è³ªãèŠæš¡åã³éè¡æ¹æ³ã䞊ã³ã«è¢«å®³è
ã«å¯Ÿãã圱é¿çã®èŠçŽ ã¯å
šãŠæå®ã®äºä»¶ã®éãã®ææšãšãªãïŒã±ãã¢ç¬¬15æ¡æ±ºå®æžãparas.60-62; Co te d'Ivoire 第 15 æ¡æ±ºå®æžããã©ã°ã©ã 203-205; Georgia 第 15 æ¡æ±ºå®æžããã©ã51).
åŸã£ãŠãéåã«é¢ããæ€å¯åŽã®æåºç©ã¯ã1ã€ãŸãã¯è€æ°ã®æœåšçäºä»¶ã®éåããããããç¶æ³å
šäœã®éåã®è©äŸ¡ã«é¢ãããã®ã§ããã
å©çšå¯èœãªæ
å ±ã«åºã¥ããæ¬æžã«èšèŒãããè±åœæ¿åºã®ã¡ã³ããŒããã³äžçã®æå°è
ã«ãã£ãŠè¡ããããšãããç¯çœªã«é¢ããæœåšçãªäºä»¶ã¯ãè£å€æã«ãããããªãè¡åãæ£åœåããã®ã«ååãªé倧æ§ãæããŠããã
çæã®ç¯çœªã¯å€§èŠæš¡ã«è¡ããã殺人ãçµç¹çã«è¡ããããšã®å ±åãããã
æ£çŸ©ã®å©ç
è±åœã§è¡ãããç¯çœªã®æ·±å»ããšçšåºŠã¯ããããã®ç¯çœªã圱é¿ãåãŒã人ã
ã®ç¯å²ããããã®ç¯çœªãç¶ç¶ããŠè¡ãããŠããããšãå 害è
ã®ç¯å²ã®åºããç¯çœªã®ãã¿ãŒã³ã®ç¹°ãè¿ããåœã¬ãã«ã§ã®èª¬æ責任ã®èŠèŸŒã¿ã®äœãã«ãã£ãŠåŒ·èª¿ããããããã¯ãã¹ãŠææ»ã«å€§ããæå©ã«åããŸãã
ãã®ãããªç¶æ³ã®äžã§ãç¯çœªãšããããã®ã®è¢«å®³è
ã¯ãæ£çŸ©ãè¡ãããã®ãèŠãããšããææãè¡šæããŠãããæã
ã¯ãè±åœå
ã®è¢«å®³è
å£äœãšçŽæ¥åè°ãããŸãéä¿¡ãäžè¬ã«å
¥æå¯èœãªæ
å ±ã調æ»ããããšã«ãã£ãŠã被害è
ã®é¢å¿ã確èªããããåªããã
ç¯ãããè¡çºã®é倧æ§ãšããã®ç¶æ³äžã§æãé倧ãªç¯çœªã«è²¬ä»»ããããšæããã人ã
ã«å¯Ÿããé¢é£ããåœå
蚎èšãååšããªãããšãèæ
®ãããšããã®ç¶æ³ã®èª¿æ»ããçããã§ãããæœåšçäºä»¶ã¯èªããããã ãããç¯çœªã®é倧æ§åã³è¢«å®³è
ã®å©çãèæ
®ããããšã
ææ»ãæ£çŸ©ã®å©çã«ãªããªããšä¿¡ããã«è¶³ãå®è³ªçãªçç±ããªãããšã
148 çµéšã«ããã°ãäžåŠçœ°ã¯ç¯çœªã®éè¡ãæªåãããèŠå ã§ããã
149 調æ»éå§ã®ããã«äºå¯©å®€ãæŒããããšãã決å®ã¯ãè±åœããã³äžçã®äººæ°ããæè¿ãããã§ãããã
150 ãã®æ±ºå®ã¯ãçŸåšè¡ãããŠããç¯çœªã«å¯Ÿå¿ãããã®ã§ãããããç¹ã«æçšãªåœ¹å²ãæããã§ããããå°ãªããšã矩åä»ããããã¯ã¯ãã³æ¥çš®ãšã¯ã¯ãã³ãã¹ããŒãã®ç¯å²ã§ã¯ãå¿
ç¶çã«æ
£è¡ã«å€åãããããã ãããããã®æ±ºå®ã«ãã£ãŠããããã®m-RNAæ²»çã«ãã£ãŠæ°ãã«å·ã€ã人ã®æ°ãå¶éããŠåœãæãããšãã§ããã ããã
151 調æ»ã®èŠè«ã¯ãèŠçšã®åºæºãæºãããŠãããäžåŠçœ°ãšã®éãã«ãããé²å±ãæ§æããæçµçã«ç§ãã¡ãç¥ã£ãŠãã人é¡ã®çåã確ä¿ããããšã«ãªãã§ãããã
152 ãããŠæ£çŸ©ã¯ãªããã
153 ç¹°ãè¿ãïŒICCã¯ãããããã¹ãŠãèæ
®ããäžã§ãã³ããã¯ã¯ãã³æ¥çš®ã®å±éãéæ³ãªã¯ã¯ãã³æ¥çš®ãã¹ããŒãã®å°å
¥ããã®ä»ããã«è¿°ã¹ããã¹ãŠã®çš®é¡ã®ãçŸåšã€ã®ãªã¹ã®äººã
ã«å¯ŸããŠè¡ãããŠããéæ³ãªæŠäºããå³æã®è£å€æåœä»€ã«ãã£ãŠåæ¢ããããã®è¡åãèµ·ããããšããæãç·æ¥ã®èª²é¡ã§ããã
Mayo97ããã翻蚳ããŠãã ãããŸããã®ã§
ãã¡ãã貌ã£ãŠãããŸãðâšïŒPDFïŒ